Gamma secretase modulators

This application is entered into national stage examination under 37 U.S.C. 371 and stems from international patent application No. PCT/US2009/063993 filed on Nov. 11, 2009, which claims priority to application No. 61/114147 filed Nov. 13, 2008.

This application claims the benefit of U.S. Provisional Application Ser. No. 61/114,147 filed Nov. 13, 2008.

The present invention relates to certain heterocyclic compounds useful as gamma secretase modulators (including inhibitors, antagonists and the like), pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat various diseases including central nervous system disorders such as, for example, neurodegenerative diseases such as Alzheimer's disease and other diseases relating to the deposition of amyloid protein. They are especially useful for reducing Amyloid beta (hereinafter referred to as Aβ production which is effective in the treatment of diseases caused by Aβ such as, for example, Alzheimers and Down Syndrome.

Alzheimer's disease is a disease characterized by degeneration and loss of neurons and also by the formation of senile plaques and neurofibrillary change. Presently, treatment of Alzheimer's disease is limited to symptomatic therapies with a symptom-improving agent represented by an acetylcholinesterase inhibitor, and the basic remedy which prevents progress of the disease has not been developed. A method of controlling the cause of onset of pathologic conditions needs to be developed for creation of the basic remedy of Alzheimer's disease.

Aβ protein, which is a metabolite of amyloid precursor protein (hereinafter referred to as APP), is considered to be greatly involved in degeneration and loss of neurons as well as onset of demential conditions (for example, see Klein W L, et al Proceeding National Academy of Science USA , Sep. 2, 2003, 100(18), p. 10417-22, suggest a molecular basis for reversible memory loss.

Nitsch R M, and 16 others, Antibodies against β - amyloid slow cognitive decline in Alzheimer's disease, Neuron , May 22, 2003, 38(4), p. 547-554) suggest that the main components of Aβ protein are Aβ40 consisting of 40 amino acids and Aβ42 having two additional amino acids at the C-terminal. The Aβ40 and Aβ42 tend to aggregate (for example, see Jarrell J T et al, The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease , Biochemistry, May 11, 1993, 32(18), p. 4693-4697) and constitute main components of senile plaques (for example, (Glenner G G, et al, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein , Biochemical and Biophysical Research Communications, May 16, 1984, 120(3), p. 885-90. See also Masters C L, et al, Amyloid plaque core protein in Alzheimer disease and Down syndrome , Proceeding National Academy of Science USA, June 1985, 82(12), p. 4245-4249.).

Furthermore, it is known that mutations of APP and presenelin genes, which is observed in familial Alzheimer's disease, increase production of Aβ40 and Aβ42 (for example, see Gouras G K, et al, Intraneuronal Aβ 42 accumulation in human brain , American Journal of Pathology, January 2000, 156(1), p. 15-20. Also, see Scheuner D, et al, Nature Medicine, August 1996, 2(8), p. 864-870; and Forman M S, et al, Differential effects of the Swedish mutant amyloid precursor protein on β - amyloid accumulation and secretion in neurons and normeuronal cells , Journal of Biological Chemistry, Dec. 19, 1997, 272(51), p. 32247-32253.). Therefore, compounds which reduce production of Aβ40 and Aβ42 are expected as an agent for controlling progress of Alzheimer's disease or for preventing the disease.

These Aβs are produced when APP is cleaved by beta secretase and subsequently clipped by gamma secretase. In consideration of this, creation of inhibitors of γ secretase and β secretase has been attempted for the purpose of reducing production of Aβs. Many of these secretase inhibitors already known are peptides or peptidomimetics such as L-685,458. L-685,458, an aspartyl protease transition stale mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity, Biochemistry, Aug. 1, 2000, 39(30), p. 8698-8704).

Also of interest in connection with the present invention are: US 2007/0117798 (Eisai, published May 24, 2007); US 2007/0117839 (Eisai, published May 24, 2007); US 2006/0004013 (Eisai, published Jan. 5, 2006); WO 2005/110422 (Boehringer Ingelheim, published Nov. 24, 2005); WO 2006/045554 (Cellzone AG, published May 4, 2006); WO 2004/110350 (Neurogenetics™, published Dec. 23, 2004); WO 2004/071431 (Myriad Genetics, published Aug. 26, 2004); US 2005/0042284 (Myriad Genetics, published Feb. 23, 2005) and WO 2006/001877 (Myriad Genetics, published Jan. 5, 2006).

There is a need for new compounds, formulations, treatments and therapies to treat diseases and disorders associated with Aβ. It is, therefore, an object of this invention to provide compounds useful in the treatment or prevention or amelioration of such diseases and disorders.

In its many embodiments, the present invention provides a novel class of heterocyclic compounds as gamma secretase modulators (including inhibitors, antagonists and the like), methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with the Aβ using such compounds or pharmaceutical compositions.

The compounds of this invention (Formula I) can be useful as gamma secretase modulators and can be useful in the treatment and prevention of diseases such as, for example, Alzheimers disease, mild cognitive impairment (MC1), Downs Syndrome, Glaucoma (Guo et. al., Proc. Natl. Acad. Sci. USA 104, 13444-13449 (2007)), Cerebral amyloid angiopathy, stroke or dementia (Frangione et al., Amyloid: J. Protein folding Disord. 8, suppl. 1, 36-42 (2001), Microgliosis and brain inflammation (M P Lamber, Proc. Natl. Acad. Sci. USA 95, 6448-53 (1998)), Olfactory function loss (Getchell, et al. Neurobiology of Aging, 663-673, 24, 2003).

This invention provides compounds of formula I:

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein R 1 , R 2 , R 6 , R 7 , R 8 , R 9 , R 10 , G, U and W are independently selected and are as defined below.

This invention also provides compounds of formula I.

The present invention further includes the compound of formula I in all its isolated forms.

This invention also provides compounds of formula I in pure and isolated form.

This invention also provides compounds of formula I selected from the group consisting of: compounds of formulas Z1 to Z24.

This invention also provides compounds of formula I selected from the group consisting of: compounds 1 to 117, the final compound of Method T and the final compound of Method U.

This invention also provides compounds of formula I selected from the group consisting of: compounds 1 to 68.

This invention also provides pharmaceutical compositions comprising an effective amount of one or more (e.g., one) compounds of formula I, or a pharmaceutically acceptable salt, ester or solvate thereof, and a pharmaceutically acceptable carrier.

This invention also provides pharmaceutical compositions comprising an effective amount of one or more (e.g., one) compounds of formula I, or a pharmaceutically acceptable salt, ester or solvate thereof, and an effective amount of one or more (e.g., one) other pharmaceutically active ingredients (e.g., drugs), and a pharmaceutically acceptable carrier.

The compounds of Formula I can be useful as gamma secretase modulators and can be useful in the treatment and prevention of diseases such as, for example, central nervous system disorders such as Alzheimers disease and Downs Syndrome.

Thus, this invention also provides methods for: (1) method for modulating (including inhibiting, antagonizing and the like) gamma-secretase; (2) treating one or more neurodegenerative diseases; (3) inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain); (4) Alzheimer's disease; and (5) treating Downs syndrome; wherein each method comprises administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of such treatment.

This invention also provides combination therapies for (1) modulating gamma-secretase, or (2) treating one or more neurodegenerative diseases, or (3) inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (4) treating Alzheimer's disease. The combination therapies are directed to methods comprising the administration of an effective amount of one or more (e.g. one) compounds of formula I and the administration of an effective amount of one or more (e.g., one) other pharmaceutical active ingredients (e.g., drugs).

This invention also provides methods for: (1) treating mild cognitive impairment; (2) treating glaucoma; (3) treating cerebral amyloid angiopathy; (4) treating stroke; (5) treating dementia; (6) treating microgliosis; (7) treating brain inflammation; and (8) treating olfactory function loss; wherein each method comprises administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of such treatment.

This invention also provides a kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of formula I in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described below), the combined quantities of the compound of formula I and the other pharmaceutically active ingredient being effective to treat the diseases or conditions mentioned in any of the above methods.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula I is selected from the group consisting of: compounds of formulas Z1 to Z24.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula I is selected from the group consisting of: compounds compounds 1 to 117, the final compound of Method T and the final compound of Method U.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula I is selected from the group consisting of: compounds compounds 1 to 68.

In one embodiment, the present invention discloses compounds which are represented by structural Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein the various moieties are described below.

Thus, one embodiment is directed to a compound of formula I:

or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

either

(i) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (ii) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (iii)

(a) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (3) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (4) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (b) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (3) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (4) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (c) said R 2 and R 6 cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or

(iv) R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )— G moiety, are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (v) R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein; (a) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (c) said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (vi) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring, wherein

(a) said spiro cycloalkyl ring is a 3 to 8 carbon membered ring (including the carbon atom common to both rings), and (b) said spiro cycloalkenyl ring is a 5 to 8 carbon membered ring (including the carbon atom common to both rings) comprising one or two double bonds (and in one example one double bond, and in another example two double bonds), provided that there is no double bond to the carbon common to both rings and (c) said spiro heterocycloalkyl ring is a 4 to 8 membered ring (including the carbon atom common to both rings) comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl (e.g., P(O)CH 3 ), P(O)Oalkyl (e.g., P(O)OCH 3 ), S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), and (d) said spiro heterocycloalkenyl ring is a 5 to 8 membered ring (including the carbon atom common to both rings) comprising one or two double bonds (and in one example one double bond, and in another example two double bonds), and comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl (e.g., P(O)CH 3 ), P(O)Oalkyl (e.g., P(O)OCH 3 ), S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), provided that there is no double bond to the carbon common to both rings, and (e) wherein said spiro ring is optionally fused with an aryl ring (e.g. phenyl), or is optionally fused with a heteroaryl ring (e.g., pyridyl), to form a fused spiro ring moiety, and (f) wherein said spiro ring, or said fused spiro ring, is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ); or

(vii) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring, wherein

(a) said spiro cycloalkyl ring is a 3 to 8 carbon membered ring (including the carbon atom common to both rings), and (b) said spiro cycloalkenyl ring is a 5 to 8 carbon membered ring (including the carbon atom common to both rings) comprising one or two double bonds (and in one example one double bond, and in another example two double bonds), provided that there is no double bond to the carbon common to both rings and (c) said spiro heterocycloalkyl ring is a 4 to 8 membered ring (including the carbon atom common to both rings) comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl (e.g., P(O)CH 3 ), P(O)Oalkyl (e.g., P(O)OCH 3 ), S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), and (d) said spiro heterocycloalkenyl ring is a 5 to 8 membered ring (including the carbon atom common to both rings) comprising one or two double bonds (and in one example one double bond, and in another example two double bonds), and comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl (e.g., P(O)CH 3 ), P(O)Oalkyl (e.g., P(O)OCH 3 ), S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), provided that there is no double bond to the carbon common to both rings, and (e) wherein said spiro ring is optionally fused with an aryl ring (e.g. phenyl), or is optionally fused with a heteroaryl ring (e.g., pyridyl), to form a fused spiro ring moiety, and (f) wherein said spiro ring is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ); or

(viii) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 -G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring (that is one R 3 on one carbon, and one R 4 on the adjacent carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are taken together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring), wherein

(a) said cycloalkyl ring is a 3 to 8 carbon membered ring (including the carbon atoms common to both rings), and (b) said cycloalkenyl ring is a 5 to 8 carbon membered ring (including the carbon atoms common to both rings) comprising one or two double bonds (and in one example one double bond, and in another example two double bonds), provided that there is no double bond to the carbon common to both rings and (c) said heterocycloalkyl ring is a 4 to 8 membered ring (including the carbon atoms common to both rings) comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl (e.g., P(O)CH 3 ), P(O)Oalkyl (e.g., P(O)OCH 3 ), S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), and (d) said heterocycloalkenyl ring is a 5 to 8 membered ring (including the carbon atoms common to both rings) comprising one or two double bonds (and in one example one double bond, and in another example two double bonds), and comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl (e.g., P(O)CH 3 ), P(O)Oalkyl (e.g., P(O)OCH 3 ), S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), provided that there is no double bond to the carbon common to both rings, and (e) wherein said ring (as described in (a) to (d)) is optionally fused with an aryl ring (e.g. phenyl), or is optionally fused with a heteroaryl ring (e.g., pyridyl), to form a fused ring moiety, and (f) wherein said ring (as described in (a) to (e) is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ); or

(ix) (a) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )-G moiety, are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (iv) above (those skilled in the art will appreciate that reference to the definitions in (i) and (iv) above is reference to the entire definitions in (i) and (iv)); or (x) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring as described in (vi) above (those skilled in the art will appreciate that reference to the definitions in (i) and (vi) above is reference to the entire definitions in (i) and (vi)); or (xi) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring as described in (vii) above (those skilled in the art will appreciate that reference to the definitions in (i) and (vii) above is reference to the entire definitions in (i) and (vii)); or (xii) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring as described in (viii) above (those skilled in the art will appreciate that reference to the definitions in (i) and (iv) above is reference to the entire definitions in (i) and (viii)); or (xiii) (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); and

U is C(R 5 ) or N;

W is selected from the group consisting of a bond, —NH—, —O—, —C(O)—, —S—, —S(O)—, —S(O 2 )—, and —C(R 11 )(R 12 )—;

G is selected from the group consisting of —C(R 3 )(R 4 )— (wherein R 3 and R 4 are independently selected), —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), —C(O)— and —N(R 13 )—, with the proviso that when W is —O— or —S—, G is not —N(R 13 )— or —C(O)—, and with the proviso that when G is —(C(R 3 )(R 4 )) 2 — then W is not a bond, and with the proviso that when G is —N(R 13 )—, then W is not —NH—;

V is selected from the group consisting of a bond, —O—, —C(O)— and —N(R 14 )—;

Each R 1 (when R 1 is not joined to R 2 ), R 2 (when R 2 is not joined to R 1 or R 6 ), R 5 , R 6 (when R 6 is not joined to R 2 ), and R 7 is independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents; or

R 6 and R 7 are taken together to form ═O, and R 1 , R 2 , and R 5 are as defined above;

or, alternatively, R 1 (when R 1 is not joined to R 2 ) and R 8 are taken together to form a bond (i.e., there is a triple bond between the carbon atom to which R 1 was bonded to and the carbon to which R 8 was bonded to, i.e., the compound of formula I is a compound of formula II:

and G, U, V, W R 2 , R 6 , R 7 , R 9 and R 10 are as defined for formula I;

Each R 3 is independently selected from the group consisting of H, halo (and in one example, F), —OR 16 (and in one example R 15 is H), —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —C(O)R 15 , —C(O)OR 15 , —C(═NOR 15 )R 16 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 16 )(OR 16 ), ═NOR 18 , —N 3 , alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkyl alkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents; or

R 3 and R 6 taken together form a bond (i.e., R 3 and R 6 form a bond between G and the carbon to which R 6 is bound), provided that when R 3 and R 6 form a bond: (1) W is not a bond, (2) R 2 and R 6 are not joined together to form a cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety (as described in (ii) and (iii) above), (3) R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together to form a cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety (as described in (iv) above), (4) R 6 and R 13 of the —N(R 13 )— G moiety are not joined together to form a heterocyclyl or heterocyclenyl moiety (as described in (v) above, (5) R 3 and R 4 , when G is —C(R 3 )(R 4 )—, are not joined to form a bond (as described in (vi) above); and (6) R 3 and R 4 , on the carbon adjacent to the carbon to which R 6 is bound, when G is —(C(R 3 )(R 4 )) 2 —, are not joined to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring (as described in (vii) above);

Each R 4 , R 11 and R 12 is independently selected from the group consisting of H, halo (and in one example, F), —OR 15 (and in one example R 15 is H), —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —C(O)R 15 , —C(O)OR 15 , —C(═NOR 15 )R 16 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , —N 3 , alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkyl alkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents, and

provided that when one of R 3 or R 4 is selected from the group consisting of: —OR 15 , —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , and —N 3 , then the other is not selected from the group consisting of: —OR 15 , —CN, —SR 15 , and —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , and —N 3 (i.e., if one of R 3 or R 4 is —OR 15 , —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , or —N 3 , then the other one is not —OR 15 , —CN, —SR 15 , and —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , or —N 3 ); and

provided that when one of R 11 or R 12 is selected from the group consisting of: —OR 15 , —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , and —N 3 , then the other is not selected from the group consisting of: —OR 15 , —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , and —N 3 (i.e., if one of R 11 or R 12 is —OR 15 , —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , or —N 3 , then the other is not —OR 15 , —CN, —SR 15 , —NR 15 R 16 , —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —S(O)R 15 , —S(O) 2 R 24 , —P(O)(OR 15 )(OR 16 ), ═NOR 15 , or —N 3 );

R 13 is independently selected from the group consisting of H, alkyl, arylalkyl-, heteroarylalkyl-, cycloalkylalkyl-, heterocycloalkylalkyl-, arylcycloalkylalkyl-, heteroarylcycloalkylalkyl-, arylheterocycloalkylalkyl-, heteroarylheterocycloalkylalkyl-, cycloalkyl, arylcycloalkyl-, heteroarylcycloalkyl-, heterocycloalkyl-, aryl heterocycloalkyl-, heteroarylheterocycloalkyl-, alkenyl, arylalkenyl-, cycloalkenyl, arylcycloalkenyl-, heteroarylcycloalkenyl-, heterocycloalkenyl-, arylheterocycloalkenyl-, heteroarylheterocycloalkenyl-, alkynyl, arylalkynyl-, aryl, cycloalkylaryl-, heterocycloalkylaryl-, heterocycloalkenylaryl-, heteroaryl, cycloalkylheteroaryl-, heterocycloalkylheteroaryl-, cycloalkenylaryl-, heterocycloalkenylaryl-, —OR 15 , —CN, —C(O)R 8 , —C(O)OR 9 , —S(O)R 10 , —S(O) 2 R 10 —S(O)N(R 11 )(R 12 ), —S(O) 2 N(R 11 )(R 12 ), —NO 2 , —N═C(R 8 ) 2 and —N(R 8 ) 2 ; and wherein said R 13 alkyl, arylalkyl-, heteroarylalkyl-, cycloalkylalkyl-, heterocycloalkylalkyl-, arylcycloalkylalkyl-, heteroarylcycloalkylalkyl-, arylheterocycloalkylalkyl-, heteroaryl heterocycloalkylalkyl-, cycloalkyl, arylcycloalkyl-, heteroarylcycloalkyl-, heterocycloalkyl, arylheterocycloalkyl-, heteroarylheterocycloalkyl-, alkenyl, arylalkenyl-, cycloalkenyl, arylcycloalkenyl-, heteroarylcycloalkenyl-, heterocycloalkenyl-, arylheterocycloalkenyl-, heteroarylheterocycloalkenyl-, alkynyl, arylalkynyl-, aryl, cycloalkylaryl-, heterocycloalkylaryl-, heterocycloalkenylaryl-, heteroaryl, cycloalkylheteroaryl-, heterocycloalkylheteroaryl-, cycloalkenylaryl-, and heterocycloalkenylaryl- groups are optionally substituted with 1 to 5 groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl-, cycloalkenyl, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, halo, —CN, —OR 15 , —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —SR 15 , —S(O)N(R 15 )(R 16 ), —CH(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —R 15 ; —CH 2 N(R 15 )(R 16 ), —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —CH 2 —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —S(O)R 15 , ═NOR 15 , —N 3 , —NO 2 and —S(O) 2 R 24 ;

R 8 is selected from the group consisting of H, halo (e.g., F), alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, with each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- being optionally substituted with 1-3 independently selected R 21 substituents;

R 9 is selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each R 9 group is optionally substituted with 1-3 independently selected R 21 substituents;

R 10 is selected from the group consisting of a bond, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclylalkyl- and the moieties:

wherein X is selected from the group consisting of; O, N(R 14 ) and S;

wherein each of said R 10 groups (except for the bond) is optionally substituted with 1-3 independently selected R 21 substituents;

R 14 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl-, cycloalkenyl, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, —CN, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , and —P(O)(OR 15 )(OR 16 ), wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl-, cycloalkenyl, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, and heteroarylalkyl- is optionally substituted with 1-5 independently selected R 21 substitutents;

Each R 15A is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl-, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, arylcycloalkyl-, arylheterocyclyl-, (R 18 ) r -alkyl, (R 18 ) r -cycloalkyl-, (R 18 ) r -cycloalkylalkyl-, (R 18 ) r -heterocyclyl-, (R 18 ) r -heterocyclylalkyl-, (R 18 ) r -aryl-, (R 18 ) r -arylalkyl-, (R 18 ) r -heteroaryl- and (R 18 ) r -heteroarylalkyl-, wherein r is 1 to 5 and each R 18 is independently selected (and those skilled in the art will appreciate that the R 18 moieties can be bound to any available substitutable atom);

R 15 , R 16 and R 17 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl-, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, arylcycloalkyl-, arylheterocyclyl-, (R 18 ) r -alkyl-, (R 18 ) r -cycloalkyl-, (R 18 ) r -cycloalkylalkyl-, (R 18 ) r -heterocyclyl-, (R 18 ) r -heterocyclylalkyl-, (R 18 ) r -aryl, (R 18 ) r -arylalkyl-, (R 18 ) r -heteroaryl- and (R 18 ) r -heteroarylalkyl-, wherein r is 1-5;

Each R 18 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl-, arylalkenyl-, arylalkynyl-, —NO 2 , halo, heteroaryl, HO-alkyoxyalkyl-, —CF 3 , —CN, alkyl-CN, —C(O)R 19 , —C(O)OH, —C(O)OR 19 , —C(O)NHR 20 , —C(O)NH 2 , —C(O)NH 2 —C(O)N(alkyl) 2 , —C(O)N(alkyl)(aryl), —C(O)N(alkyl)(heteroaryl), —SR 19 , —S(O) 2 R 20 , —S(O)NH 2 , —S(O)NH(alkyl), —S(O)N(alkyl)(alkyl), —S(O)NH(aryl), —S(O) 2 NH 2 , —S(O) 2 NHR 19 , —S(O) 2 NH(heterocyclyl), —S(O) 2 N(alkyl) 2 , —S(O) 2 N(alkyl)(aryl), —OCF 3 , —OH, —OR 20 , —O-heterocyclyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH 2 , —NHR 20 , —N(alkyl) 2 , —N(arylalkyl) 2 , —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R 20 , —NHC(O)NH 2 , —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O) 2 R 20 , —NHS(O) 2 NH(alkyl), —NHS(O) 2 N(alkyl)(alkyl), —N(alkyl)S(O) 2 NH(alkyl) and —N(alkyl)S(O) 2 N(alkyl)(alkyl);

or, alternately, two R 18 moieties on adjacent carbons can be linked together to form:

R 19 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl- and heteroarylalkyl-;

R 20 is selected from the group consisting of: alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl-, heteroaryl and heteroarylalkyl-;

Each R 21 group is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, halo, —CN, —OR 15 —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —SF 5 , —OSF 5 , —Si(R 24 ) 3 wherein each R 24 is independently selected, —SR 15 , —S(O)N(R 15 )(R 16 ), —CH(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —R 15 ; —CH 2 N(R 15 )(R 16 ), —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —CH 2 —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —S(O)R 15 , ═NOR 15 , —N 3 , —NO 2 and —S(O) 2 R 24 ; and wherein each of the R 21 alkyl, cycloalkenyl, cycloalkyl, cycloalkylalkyl-, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, alkenyl and alkynyl groups is optionally substituted with 1 to 5 independently selected R 22 groups;

Each R 22 is independently selected from the group consisting of: alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, halo, —CF 3 , —CN, —OR 15 , —C(O)R 15 , —C(O)OR 15 , -alkyl-C(O)OR 15 , C(O)N(R 15 )(R 16 ), —SF 5 , —OSF 5 , —Si(R 24 ) 3 wherein each R 24 is independently selected —SR 15 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16 , —N(R 15 )S(O) 2 R 16 , —CH 2 —N(R 15 )S(O) 2 R 16 , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —N 3 , ═NOR 15 , —NO 2 , —S(O)R 15 and —S(O) 2 R 24 ; and

Each R 24 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl-, heterocyclyl, heterocyclylalkyl-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, arylcycloalkyl-, aryl heterocyclyl-, (R 18 ) r -alkyl-, (R 18 ) r -cycloalkyl-, (R 18 ) r -cycloalkylalkyl-, (R 18 ) r -heterocyclyl-, (R 18 ) r -heterocyclylalkyl-, (R 18 ) r -aryl-, (R 18 ) r -arylalkyl-, (R 18 ) r -heteroaryl- and (R 18 ) r , -heteroarylalkyl- (wherein R 18 and r are as defined above); and

With the proviso that:

(a) G is —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected); or (b) there is present at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected), and when there is more than one group, each group is independently selected, or (c) there is present an R 10 group selected from the group consisting of:

(and in one embodiment there is present an R 10 group selected from the group consisting of:

and in another embodiment there is present an R 10 group selected from the group consisting of:

and in another embodiment there is present an R 10 group selected from the group consisting of:

(d) there is present a spiro ring formed by joining R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring (i.e., there is present a spiro ring described in (vi) above); or

(e) there is present a spiro ring formed by joining one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring (as described in (vii) above), or

(f) there is present a ring formed by joining an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring (as described in (viii) above), or

(g) none of the rings described above in (i) to (xii) are present (that is (1) R 1 and R 2 are not joined together, and (2) R 2 and R 6 are not joined together, and (3) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (4) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (5) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (6) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together), (7) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together), (8) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, (9) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, (10) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, (11) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (12) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above), or

(h) there is present a ring formed by joining R 1 and R 2 together as described in (i) above, and there is present a ring formed by joining R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )— G moiety together as described in (iv) above; or

(i) there is present a ring formed by joining R 1 and R 2 together as described in (i) above, and (b) there is present a ring formed by joining R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety together as described in (vi) above; or

(j) there is present a ring formed by joining R 1 and R 2 together as described in (i) above, and there is present a ring formed by joining one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety together as described in (vii) above; or

(k) there is present a ring formed by joining R 1 and R 2 together as described in (i) above, and there is present a ring formed by joining an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety together as described in (viii) above; or

(l) R 6 and R 7 are taken together to form ═O.

In one embodiment of this invention:

(a) Each R 1 (when R 1 is not joined to R 2 ), R 2 (when R 2 is not joined to R 1 or R 6 ), R 5 , R 6 (when R 6 is not joined to R 2 ), and R 7 in formula I is independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents; (b) the remaining substituents for formula I are as defined for formula I above; and (c) at least one of provisos (a) to (k) is present for the compounds of formula I.

While provisos (a) to (l) are given in the alternative, more than one proviso can be present in the compounds of formula I. Thus, in one embodiment of the compounds of formula I there is present at least two (e.g., 2, 3, 4, or 5) provisos selected from the group consisting of provisos (a) to (l) provided that one proviso does not exclude another proviso. Thus:

(i) proviso (a) is not present when provisos (d), (e), (f), or (h) to (k) is present, and (ii) proviso (d) is not present when proviso (a), (e) (f), or (h) to (k) is present, and (iii) proviso (g) is not present when provisos (d), (e), (f) or (h) to (k) is present, and (iv) when there is more than one proviso present, and one proviso is selected from the group consisting of provisos (d), (e), (f), and (h) to (k) is present, then the remaining provisos are selected from the group consisting of: (b) and (c).

Also, proviso (h) is not present when proviso (l) is present. Thus, when there is more than one proviso present, and one proviso is selected from the group consisting of provisos (d), (e), (f), and (i) to (l) is present, then the remaining provisos are selected from the group consisting of: (b) and (c).

Examples of the compounds of formula I include compounds wherein: (1) provisos (a) and (b) are present, (2) provisos (a) and (c) are present, (3) provisos (a) and (e) are present, (4) provisos (a) and (f) are present, (5) provisos (a) and (g) are present, (6) provisos (b) and (c) are present, (7) provisos (b) and (d) are present, (8) provisos (b) and (e) are present, (9) provisos (b) and (f) are present, (10) provisos (b) and (g) are present, (11) provisos (c) and (d) are present, (12) provisos (c) and (e) are present, (13) provisos (c) and (f) are present, (14) provisos (c) and (g) are present, (15) provisos (d) and (g) are present, (16) provisos (e) and (g) are present, (17) provisos (a), (b) and (c) are present, (18) provisos (a), (b) and (g) are present, (18) provisos (a) (c) and (e) are present, (19) provisos (a) (c) and (f) are present, (20) provisos (a) (c) and (g) are present, (21) provisos (b), (c) and (d) are present, (22) provisos (b), (c) and (e) are present, (23) provisos (b), (c) and (f) are present, (24) provisos (b), (c) and (g) are present, (25) provisos (a), (b), (c) and (g) are present, and (26) provisos (b), (c), (d) and (g) are present.

In another example of the compounds of formula I, proviso I is present.

One embodiment of this invention is directed to compounds of formula I wherein (a) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )-G moiety, are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (iv) above.

Another embodiment of this invention is directed to compounds of formula I wherein R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring as described in (vi) above.

Another embodiment of this invention is directed to compounds of formula I wherein R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring as described in (vii) above.

Another embodiment of this invention is directed to compounds of formula I wherein R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety as described in (i) above, and (b) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring as described in (viii) above.

Those skilled in the art will appreciate that the —SF 5 , —OSF 5 , and —Si(R 24 ) 3 groups are present in the compounds of formula I: (a) due to the presence of at least one R 21 group that is selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 , or (b) due to the presence of at least one R 22 substituent on at least one R 21 group, wherein said R 22 substituent is selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 , and wherein said R 21 group is other than a —SF 5 , —OSF 5 , or —Si(R 24 ) 3 group.

The compounds of this invention are useful for treating central nervous system disorders such as, for example, neurodegenerative diseases such as Alzheimer's disease and other diseases relating to the deposition of amyloid protein. They are especially useful for reducing Amyloid beta (hereinafter referred to as Aβ) production which is effective in the treatment of diseases caused by Aβ such as, for example, Alzheimers and Down Syndrome.

Thus, for example, the compounds of this invention can be used to treat the following diseases or conditions: Alzheimers disease, mild cognitive impairment (MCI), Downs Syndrome, Glaucoma (Guo et. al., Proc. Natl. Acad. Sci. USA 104, 13444-13449 (2007)), Cerebral amyloid angiopathy, stroke or dementia (Frangione et al., Amyloid: J. Protein folding Disord. 8, suppl. 1, 36-42 (2001), Microgliosis and brain inflammation (M P Lamber, Proc. Natl. Acad. Sci. USA 95, 6448-53 (1998)), and Olfactory function loss (Getchell, et. al. Neurobiology of Aging, 663-673, 24, 2003).

One embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )— (wherein each R 3 and each R 4 are independently selected), and all other substituents are as defined for formula I. One embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), and all other substituents are as defined for formula I.

Another embodiment of this is directed to compounds of formula I wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 is present, and wherein each R 24 is independently selected, and wherein when there is more than one group, each group is independently selected.

Another embodiment of this is directed to compounds of formula I wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and wherein when there is more than one group, each group is independently selected.

In one embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) is present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 is present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 , and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 , and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 is present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula f, wherein at least one group is other than —Si(R 24 ) 3 , and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, wherein at least one group is other than —Si(R 24 ) 3 , and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 .

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I, wherein at least one group is other than —Si(CH 3 ) 3 .

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 are present in the compounds of formula I, wherein at least one group is other than —Si(CH 3 ) 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 and —OSF 5 is present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 and —OSF 5 are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 and —OSF 5 are present in the compounds of formula I.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I.

In another embodiment of this invention two —SF 5 groups are present in the compounds of formula I.

In another embodiment of this invention three —SF 5 groups are present in the compounds of formula I.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I.

In another embodiment of this invention two —OSF 5 groups are present in the compounds of formula I.

In another embodiment of this invention three —OSF 5 groups are present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 and —OSF 5 is present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 and —OSF 5 are present in the compounds of formula I, no Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 and —OSF 5 are present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention two —SF 5 groups are present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention three —SF 5 groups are present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention two —OSF 5 groups are present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention three —OSF 5 groups are present in the compounds of formula I, no —Si(R 24 ) 3 groups are present, and R 10 is any of the groups defined in formula I.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected) group is present in the compounds of formula I.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected) groups are present in the compounds of formula I.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected) groups are present in the compounds of formula I.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I.

In another embodiment of this invention one —Si(R 24 ) 3 group is present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention two —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3

In another embodiment of this invention three —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention one —Si(R 24 ) 3 group is present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention two —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention three —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 .

In another embodiment of this invention one —Si(R 24 ) 3 group is present in the compounds of formula I, and said —Si(R 24 ) 3 group is —Si(CH 3 ) 3 .

In another embodiment of this invention two —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are —Si(CH 3 ) 3 .

In another embodiment of this invention three —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are —Si(CH 3 ) 3 .

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 , is present in the compounds of formula

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected) group is present in the compounds of formula I, and one or two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected) group is present in the compounds of formula I, and one or two groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) is present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 , is present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected) are present in the compounds of formula I.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) are present in the compounds of formula I.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) are present in the compounds of formula I.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected) are present in the compounds of formula I.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) are present in the compounds of formula I.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) are present in the compounds of formula I.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is the same or different alkyl group) is present in the compounds of formula I.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 15 ) 3 (wherein each R 15 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I.

Another embodiment of this invention is directed to compounds of formula I wherein R 10 is selected from the group consisting of a bond, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclylalkyl- and the moieties:

wherein X is selected from the group consisting of; O, N(R 14 ) and S;

wherein each of said R 10 groups (except for the bond) is optionally substituted with 1-3 independently selected R 21 substituents.

Another embodiment of this invention is directed to compounds of formula I wherein R 10 is selected from the group consisting of:

Another embodiment of this invention is directed to compounds of formula I wherein R 10 is selected from the group consisting of:

Another embodiment of this invention is directed to compounds of formula I wherein R 10 is selected from the group consisting of: a bond, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclylalkyl- and the moieties:

wherein X is selected from the group consisting of; O, N(R 14 ) and S;

wherein each of said R 10 groups (except for the bond) is optionally substituted with 1-3 independently selected R 21 substituents.

Another embodiment of this is directed to compounds of formula I wherein R 10 is selected from the group consisting of:

In another embodiment R 10 is selected from the group consisting of a bond, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclylalkyl- and the moieties:

wherein X is selected from the group consisting of; O, N(R 14 ) and S;

wherein each of said R 10 groups (except for the bond) is optionally substituted with 1-3 independently selected R 21 substituents.

In another embodiment R 10 is selected from the group consisting of:

Another embodiment of this is directed to compounds of formula I wherein R 10 is selected from the group consisting of: a bond, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclylalkyl- and the moieties:

wherein X is selected from the group consisting of; O, N(R 14 ) and S;

wherein each of said R 10 groups (except for the bond) is optionally substituted with 1-3 independently selected R 21 substituents. Another embodiment of this is directed to compounds of formula I wherein

R 10 is selected from the group consisting of:

Another embodiment of this invention is directed to compounds of formula I wherein W is selected from the group consisting of a bond, —O—, —O(O)—, —S—, —S(O)—, —S(O 2 )—, and —C(R 11 )(R 12 )—.

Another embodiment of this invention is directed to compounds of formula I wherein W is selected from the group consisting of a bond, —O—, —C(O)—, —S—, —S(O)—, —S(O 2 )—, and —C(R 11 )(R 12 )—; and G is selected from the group consisting of —C(R 3 )(R 4 )— (wherein R 3 and R 4 are independently selected), —(C(R 3 )(R 4 )) 2 —(wherein each R 3 and each R 4 are independently selected), —C(O)— and —N(R 13 )—, with the proviso that when W is —O— or —S—, G is not —N(R 13 )— or —C(O)—, and with the proviso that when G is —(C(R 3 )(R 4 )) 2 — then W is not a bond.

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring.

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a cycloalkyl spiro ring. One example of said cycloalkyl spiro ring is:

Another example of said cycloalkyl spiro ring is:

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a cycloalkyl spiro ring, and said cycloalkyl ring is fused with an aryl ring (e.g., phenyl) to form a fused spiro ring moiety, and said fused spiro ring moiety is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ). In one example said fused spiro ring moiety is substituted with 1-3 halos (e.g., 1-3 F). In another example said fused spiro ring moiety is substituted with 1 halo (e.g., F). In another example said aryl moiety of said fused spiro ring moiety is phenyl, and said phenyl is substituted with 1-3 halos (e.g., 1-3 F). In another example said aryl moiety of said fused spiro ring moiety is phenyl, and said phenyl is substituted with 1 halo (e.g., 1 F). In another example said cycloalkyl moiety of said fused spiro ring moiety is cyclopentyl, and said aryl moiety of said fused spiro ring moiety is phenyl. In another example said cycloalkyl moiety of said fused spiro ring moiety is cyclopentyl, and said aryl moiety of said fused spiro ring moiety is phenyl, and said fused spiro ring moiety is substituted with 1-3 substituents as described above. In another example said cycloalkyl moiety of said fused spiro ring moiety is cyclopentyl, and said aryl moiety of said fused spiro ring moiety is phenyl, and said fused spiro ring moiety is substituted with 1-3 halos (e.g., 1-3 F). In another example said cycloalkyl moiety of said fused spiro ring moiety is cyclopentyl, and said aryl moiety of said fused spiro ring moiety is phenyl, and said fused spiro ring moiety is substituted with 1 halo (e.g., 1 F). In another example said fused spiro ring moiety is:

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a cycloalkyl spiro ring, and said cycloalkyl ring is fused with an heteroaryl ring (e.g., pyridyl) to form a fused spiro ring moiety, and said fused spiro ring moiety is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ).

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a cycloalkenyl spiro ring.

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a heterocycloalkyl spiro ring. One example of said heterocycloalkyl spiro ring is:

Another example of said spiro heterocycloalkyl ring is:

Another example of said spiro heterocycloalkyl ring is:

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a heterocycloalkyl spiro ring, and said heterocycloalkyl ring is fused with an aryl ring (e.g., phenyl) to form a fused spiro ring moiety, and said fused spiro ring moiety is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 —C(═NOR 15 )R 16 , P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ). In one example said fused spiro ring moiety is substituted with 1-3 halos (e.g., 1-3 F). In another example said fused spiro ring moiety is substituted with 1 halo (e.g., F). In another example said aryl moiety of said fused spiro ring moiety is phenyl, and said phenyl is substituted with 1-3 halos (e.g., 1-3 F). In another example said aryl moiety of said fused spiro ring moiety is phenyl, and said phenyl is substituted with 1 halo (e.g., 1 F). In another example said heterocycloalkyl moiety of said fused spiro ring moiety is tetrahydrofuran, and said aryl moiety of said fused spiro ring moiety is phenyl. In another example said cycloalkyl moiety of said fused spiro ring moiety is tetrahydrofuran, and said aryl moiety of said fused spiro ring moiety is phenyl, and said fused spiro ring moiety is substituted with 1-3 substituents as described above. In another example said cycloalkyl moiety of said fused spiro ring moiety is tetrahydrofuran, and said aryl moiety of said fused spiro ring moiety is phenyl, and said fused spiro ring moiety is substituted with 1-3 halos (e.g., 1-3 F). In another example said cycloalkyl moiety of said fused spiro ring moiety is tetrahydrofuran, and said aryl moiety of said fused spiro ring moiety is phenyl, and said fused spiro ring moiety is substituted with 1 halo (e.g., 1 F). In another example said fused spiro ring moiety is:

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a heterocycloalkyl spiro ring, and said heterocycloalkyl ring is fused with an heteroaryl ring (e.g., pyridyl) to form a fused spiro ring moiety, and said fused spiro ring moiety is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ).

Another embodiment of this invention is directed to compounds of formula I wherein G is —C(R 3 )(R 4 )— and R 3 and R 4 are joined together to form a heterocycloalkenyl spiro ring.

Another embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )) 2 — and one R 3 and one R 4 on one carbon are joined together to form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl spiro ring.

Another embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), and an R 3 and an R 4 on adjacent carbons form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring (as described in (viii) above).

Another embodiment of this invention is directed to compounds of formula I selected), and an R 3 and an R 4 on adjacent carbons form a cycloalkyl ring (as described in (viii) above).

Another embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), and an R 3 and an R 4 on adjacent carbons form a cycloalkenyl ring (as described in (viii) above).

Another embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), and an R 3 and an R 4 on adjacent carbons form a heterocycloalkyl ring (as described in (viii) above).

Another embodiment of this invention is directed to compounds of formula I wherein G is —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), and an R 3 and an R 4 on adjacent carbons form a heterocycloalkenyl ring (as described in (viii) above).

Another embodiment of this invention is directed to compounds of formula I wherein none of the rings described in paragraphs (i) to (xii) of formula I are present in formula I (that is (1) R 1 and R 2 are not joined together, and (2) R 2 and R 6 are not joined together, and (3) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (4) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (5) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (6) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together) and (7) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together), and (8) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (9) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (10) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (11) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (12) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above).

Another embodiment of this invention is directed to compounds of formula I wherein the conditions described in provisos (a) and (b) are present.

Another embodiment of this invention is directed to compounds of formula I wherein: (1) proviso (a) is present, and (2) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a) and (c) are present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a) and (e) are present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a) and (f) are present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b) and (c) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (c) is present, and (2) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b) and (d) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (d) is present, and (2) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b) and (e) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (e) is present, and (2) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b) and (f) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (f) is present, and (2) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (g) is present, and (2) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (c) and (d) are present.

Another embodiment of this invention is directed to compounds of formula wherein provisos (c) and (e) are present.

Another embodiment of this invention is directed to compounds of formula wherein provisos (c) and (f) are present.

Another embodiment of this invention is directed to compounds of formula wherein provisos (c) and (g) are present.

Another embodiment of this invention is directed to compounds of formula wherein provisos (d) and (g) are present.

Another embodiment of this invention is directed to compounds of formula wherein provisos (e) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a), (b) and (c) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (a) is present, and (2) proviso (c) is present, and (3) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a), (b) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (a) is present, and (2) proviso (g) is present, and (3) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (a), (c) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b), (c) and (d) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (c) is present, and (2) proviso (d) is present, and (3) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to compounds of formula I wherein the conditions described in provisos (b), (c) and (e) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (c) is present, and (2) proviso (e) is present, and (3) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present,

Another embodiment of this invention is directed to compounds of formula I wherein the conditions described in provisos (b), (c) and (f) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (c) is present, and (2) proviso (f) is present, and (3) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present,

Another embodiment of this invention is directed to compounds of formula I wherein the conditions described in provisos (b), (c) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (c) is present, and (2) proviso (g) is present, and (3) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present.

Another embodiment of this invention is directed to compounds of formula I wherein provisos (b), (c), (d) and (g) are present.

Another embodiment of this invention is directed to compounds of formula I wherein (1) proviso (c) is present, and (2) proviso (d) is present, and (3) proviso (g) is present, and (4) wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present,

Other embodiments of this invention are directed to any one of the above embodiments directed to the provisos (either individually, or in the combinations) wherein: R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents.

Other embodiments of this invention are directed to any one of the above embodiments directed to the provisos (either individually, or in the combinations) wherein: R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; or

Other embodiments of this invention are directed to any one of the above embodiments directed to the provisos (either individually, or in the combinations) wherein: R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment of this invention R 10 in formula I is selected from the group consisting of:

In another embodiment of this invention R 10 in formula I is selected from the group consisting of:

In another embodiment of this invention R 10 is group 1A. In another embodiment of this invention R 10 is group 2A. In another embodiment of this invention R 10 is group 3A. In another embodiment of this invention R 10 is group 4A. In another embodiment of this invention R 10 is group 5A. In another embodiment of this invention R 10 is group 6A. In another embodiment of this invention R 10 is group 7A. In another embodiment of this invention R 10 is group 8A. In another embodiment of this invention R 10 is group 9A. In another embodiment of this invention R 10 is group 10A. In another embodiment of this invention R 10 is group 11A. In another embodiment of this invention R 10 is group 12A. In another embodiment of this invention R 10 is group 13A. In another embodiment of this invention R 10 is group 14A. In another embodiment of this invention R 10 is group 15A. In another embodiment of this invention R 10 is group 16A. In another embodiment of this invention R 10 is group 17A. In another embodiment of this invention R 10 is group 18A. In another embodiment of this invention R 10 is group 19A. In another embodiment of this invention R 10 is group 20A. In another embodiment of this invention R 10 is group 21A. In another embodiment of this invention R 10 is group 22A. In another embodiment of this invention R 10 is group 23A. In another embodiment of this invention R 10 is group 24A. In another embodiment of this invention R 10 is group 25A. In another embodiment of this invention R 10 is group 26A. In another embodiment of this invention R 10 is group 27A. In another embodiment of this invention R 10 is group 28A. In another embodiment of this invention R 10 is group 29A. In another embodiment of this invention R 10 is group 30A. In another embodiment of this invention R 10 is group 31A. In another embodiment of this invention R 10 is group 32A. In another embodiment of this invention R 10 is group 33A. In another embodiment of this invention R 10 is group 34A. In another embodiment of this invention R 10 is group 35A. In another embodiment of this invention R 10 is group 36A. In another embodiment of this invention R 10 is group 37A. In another embodiment of this invention R 10 is group 38A. In another embodiment of this invention R 10 is group 39A. In another embodiment of this invention R 10 is group 40A. In another embodiment of this invention R 10 is group 41A. In another embodiment of this invention R 10 is group 42A. In another embodiment of this invention R 10 is group 43A. In another embodiment of this invention R 10 is group 44A. In another embodiment of this invention R 10 is group 45A. In another embodiment of this invention R 10 is group 46A. In another embodiment of this invention R 10 is group 47A. In another embodiment of this invention R 10 is group 48A. In another embodiment of this invention R 10 is group 49A. In another embodiment of this invention R 10 is group 50A. In another embodiment of this invention R 10 is group 51A. In another embodiment of this invention R 10 is group 52A. In another embodiment of this invention R 10 is group 53A. In another embodiment of this invention R 10 is group 54A. In another embodiment of this invention R 10 is group 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 15 is independently selected) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 and —OSF 5 is present in the compounds of formula I, and R 15 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 and —OSF 5 is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 and —OSF 5 are present in the compounds of formula I, and R 15 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 and —OSF 5 are present in the compounds of formula I, and R 15 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —SF 5 groups are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —SF 5 groups are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —OSF 5 groups are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —OSF 5 groups are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected) group is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected) groups are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected) groups are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 group is present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 group is present in the compounds of formula I, and said —Si(R 24 ) 3 group is selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are independently selected from the group consisting of: —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 group is present in the compounds of formula I, and said —Si(R 24 ) 3 group is —Si(CH 3 ) 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are —Si(CH 3 ) 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three —Si(R 24 ) 3 groups are present in the compounds of formula I, and said —Si(R 24 ) 3 groups are —Si(CH 3 ) 3 and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 , is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —SF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —OSF 5 group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 24 is independently selected) group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one —Si(R 24 ) 3 (wherein each R 15 is independently selected) group is present in the compounds of formula I, and one or two additional groups selected from the group consisting of: —SF 5 and —OSF 5 are also present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 , is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) are present in the compounds of formula I, and R 10 is selected from the group consisting of IA to 55A.

In another embodiment of this invention two groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention two groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , —Si(CH 3 ) 2 -phenyl, and —Si(CH 2 CH 3 ) 2 CH 3 ) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , —Si(CH 3 ) 3 , and —Si(CH 2 CH 3 ) 2 CH 3 ) are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention three groups independently selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(CH 3 ) 3 are present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is the same or different alkyl group) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

In another embodiment of this invention at least one group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 (wherein each R 24 is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula I, and R 10 is selected from the group consisting of 1A to 55A.

Other embodiments of this invention are directed to any one of the embodiments above directed to the groups —SF 5 , —OSF 5 , or —Si(R 24 ) 3 wherein R 10 is 35A.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents;

U, W, G, V, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I; and

R 3 is as defined for formula I; or R 3 and R 6 taken together form a bond (i.e., R 3 and R 6 form a bond between G and the carbon to which R 6 is bound), provided that when R 3 and R 6 form a bond W is not a bond.

In another embodiment the compounds of formula I are compounds of formula II:

wherein G, U, V, W, R 2 , R 6 , R 7 , R 9 , and R 10 are as defined for formula I. In one embodiment of the compounds of formula II, there are 1 to 3 (in one example there is one, in another example there are 2, and in another example there are three) groups selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 present on either R 6 or R 7 (and in one example on R 6 , and in another example R 7 , and in another example distributed between R 6 and R 7 when there is more than one of said groups).

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents;

U, W, G, V, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I; and

R 3 is as defined for formula I; or R 3 and R 6 taken together form a bond (i.e., R 3 and R 6 form a bond between G and the carbon to which R 6 is bound), provided that when R 3 and R 6 form a bond W is not a bond; and

at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF S , —OSF 5 , and —Si(R 24 ) 3 is present, and wherein each R 24 is independently selected, and wherein there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents;

U, W, G, V, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I; and

R 3 is as defined for formula I; or R 3 and R 6 taken together form a bond (i.e., R 3 and R 6 form a bond between G and the carbon to which R 6 is bound), provided that when R 3 and R 6 form a bond W is not a bond; and

at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

In another embodiment of this invention, R 1 and R 2 are joined together to form a 5 to 8 membered cycloalkyl ring, and said ring is substituted with a group selected from the group consisting of —SF 5 , —OSF 5 and —Si (R 24 ) 3 . In another embodiment said ring is substituted with a group selected from the group consisting of —SF 5 and —OSF 5 . In another embodiment said ring is substituted with a —SF 5 group. In another embodiment said ring is substituted with an —OSF 5 group. In another embodiment said ring is substituted with a —Si(R 24 ) 3 group. Examples of the —Si(R 24 ) 3 group in the embodiments above include groups wherein each R 24 is the same or different alkyl group (e.g., methyl and ethyl). Thus, —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 ) are examples of the —Si(R 24 ) 3 group in the above embodiments. And in one example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 .

In another embodiment of this invention, R 1 and R 2 are joined together to form a 5 to 8 membered heterocyclyl ring, and said ring is substituted with a group selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 . In another embodiment said ring is substituted with a group selected from the group consisting of —SF 5 and —OSF 5 . In another embodiment said ring is substituted with a —SF 5 group. In another embodiment said ring is substituted with an —OSF 5 group. In another embodiment said ring is substituted with a —Si(R 24 ) 3 group. Examples of the —Si (R 24 ) 3 group in the embodiments above include groups wherein each R 24 is the same or different alkyl group (e.g., methyl and ethyl). Thus, —Si(CH 3 ) 3 and —Si(CH 2 CH 3 ) 2 CH 3 ) are examples of the —Si(R 24 ) 3 group in the above embodiments. And in one example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 .

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and

U, W, G, V, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents;

U, W, G, V, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I; and

at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 is present, and wherein each R 24 is independently selected, and wherein there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents;

U, W, G, V, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I; and

at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and

U, W, G, V, R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and

U, W, G, V, R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 24 and are as defined for formula I; and

at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 , —OSF 5 , and —Si(R 24 ) 3 is present, and wherein each R 24 is independently selected, and wherein there is more than one group, each group is independently selected.

Another embodiment of this invention is directed to a compound of the formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:

R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl or heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and

U, W, G, V, R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 , R 14 , R 15A , R 15 , R 16 , R 17 ,

R 18 , R 19 , R 20 , R 21 , R 22 and R 24 are as defined for formula I; and

at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: —SF 5 and —OSF 5 is present, and when there is more than one group, each group is independently selected.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is N.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —NH—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —O—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —C(O)—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —S—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —S—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —S(O)—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —S(O) 2 —.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein W is —C(R 11 )(R 12 )—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is N and W is —O—.

Other embodiments of this invention are directed to any one W is selected from the group consisting of a bond; —NH—, —O—, —C(O)—, —S—, —S(O)—, —S(O 2 )—, and —C(R 11 )(R 12 )—:

G is selected from the group consisting of —C(R 3 )(R 4 )— (wherein R 3 and R 4 are independently selected), —(C(R 3 )(R 4 )) 2 — (wherein each R 3 and each R 4 are independently selected), —C(O)— and —N(R 13 )—, with the proviso that when W is —O— or —S—, G is not —N(R 13 )— or —C(O)—, and with the proviso that when G is —(C(R 3 )(R 4 )) 2 — then W is not a bond, and with the proviso that when G is —N(R 13 )—, then W is not —NH—;

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is N, G is —C(R 3 )(R 4 )— and W is —O—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is N, G is —C(R 3 )(R 4 )— and W is —O—, and wherein R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are taken together with the carbon to which they are bound to form a cycloalkyl spiro ring, cycloalkenyl spiro ring, heterocycloalkyl spiro ring, or heterocycloalkenyl spiro ring.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is N, G is —(C(R 3 )(R 4 )) 2 — and W is —O—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is N, G is —(C(R 3 )(R 4 )) 2 —, and W is —O—, and wherein one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are taken together with the carbon to which they are bound to form a cycloalkyl spiro ring, cycloalkenyl spiro ring, heterocycloalkyl spiro ring, or heterocycloalkenyl spiro ring.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is CH and W is —O—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is CH, G is —C(R 3 )(R 4 )— and W is —O—, and wherein R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are taken together with the carbon to which they are bound to form a cycloalkyl spiro ring, cycloalkenyl spiro ring, heterocycloalkyl spiro ring, or heterocycloalkenyl spiro ring.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is CH, G is —(C(R 3 )(R 4 )— and W is —O—.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is CH, G is —(C(R 3 )(R 4 )) 2 —, and W is —O—, and wherein one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are taken together with the carbon to which they are bound to form a cycloalkyl spiro ring, cycloalkenyl spiro ring, heterocycloalkyl spiro ring, or heterocycloalkenyl spiro ring.

Other embodiments of this invention are directed to any one of the above formula I embodiments wherein U is CH, G is —(C(R 3 )(R 4 )) 2 —, and W is —O—.

Those skilled in the art will appreciate that for the compounds of the invention:

are isomers

Those skilled in the art will appreciate that in the compounds of the invention R 6 can be:

Those skilled in the art will appreciate that in the compounds of the invention R 7 can be:

Thus, for example, in embodiments of this invention R 6 and R 7 can be:

In other embodiments of this invention R 6 and R 7 can be:

In another embodiment, U is C(R 5 ).

In another embodiment, U is N.

In another embodiment, R 2 is H.

In another embodiment, R 2 is alkyl.

In another embodiment, R 2 is methyl.

In another embodiment, R 2 is alkoxyalkyl-.

In another embodiment, R 2 is 3-methoxypropyl-.

In another embodiment, U is N and R 2 is 3-methoxypropyl-.

In another embodiment, W is a bond.

In another embodiment, W is —NH—.

In another embodiment, W is —O—.

In another embodiment, W is —C(O)—.

In another embodiment, W is —S—.

In another embodiment, W is —S(O)—.

In another embodiment, W is —S(O 2 )—.

In another embodiment, W is —C(R 11 )(R 12 )—.

In another embodiment, ═N—W-G- is ═N—C(R 11 R 12 )—C(O)—.

In another embodiment, G is —C(R 3 )(R 4 )—.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is aryl (e.g., phenyl).

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected halos.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is phenyl substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is phenyl substituted with 1 to 3 independently selected halos.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is phenyl substituted with 1 to 3 independently selected F.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is aryl (e.g., phenyl), and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected halos, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is phenyl substituted with 1 to 3 independently selected R 21 groups, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is phenyl substituted with 1 to 3 independently selected halos, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is phenyl substituted with 1 to 3 independently selected F, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is heteroaryl (e.g., thienyl).

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected halos.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is thienyl substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is thienyl substituted with 1 to 3 independently selected halos.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is thienyl substituted with 1 to 3 independently selected F.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is heteroaryl (e.g., thienyl), and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected halos, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is thienyl substituted with 1 to 3 independently selected R 21 groups, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is thienyl substituted with 1 to 3 independently selected halos, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is thienyl substituted with 1 to 3 independently selected F, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cycloalkyl (e.g., cyclopropyl).

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cycloalkyl (e.g., cyclopropyl) optionally substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cycloalkyl (e.g., cyclopropyl) optionally substituted with 1 to 3 independently selected halos.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cyclopropyl optionally substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cyclopropyl optionally substituted with 1 to 3 independently selected halos.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cyclopropyl optionally substituted with 1 to 3 independently selected F.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cycloalkyl (e.g., cyclopropyl), and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cycloalkyl (e.g., cyclopropyl) optionally substituted with 1 to 3 independently selected R 21 groups, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cycloalkyl (e.g., cyclopropyl) optionally substituted with 1 to 3 independently selected halos, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cyclopropyl optionally substituted with 1 to 3 independently selected R 21 groups, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cyclopropyl optionally substituted with 1 to 3 independently selected halos, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is cyclopropyl optionally substituted with 1 to 3 independently selected F, and the other one of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl).

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) optionally substituted with 1 to 3 independently selected R 21 groups.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, wherein R 15 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl), and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) optionally substituted with 1 to 3 independently selected R 21 groups, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, wherein R 15 is H, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is H, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 is H, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, wherein R 15 is (R 18 ) r -alkyl- (e.g., (R 18 ) r —CH 2 —, or (R 18 ) r —(CH 2 ) 2 —), and R 18 is —OH, and r is 1.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, wherein R 15 is HO-alkyl- (e.g., HO—CH 2 —, or HO—(CH 2 ) 2 —).

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is HO-alkyl- (e.g., HO—CH 2 —, or HO—(CH 2 ) 2 —).

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 is HO-alkyl- (e.g., HO—CH 2 —, or HO—(CH 2 ) 2 —). In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is HO—CH 2 —.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 HO—CH 2 —.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is HO—(CH 2 ) 2 —.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 is HO—(CH 2 ) 2 —.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, wherein R 15 is (R 18 ) r -alkyl- (e.g., (R 18 ) r —CH 2 —, or (R 18 ) r —(CH 2 ) 2 —), and R 18 is —OH, and r is 1, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is alkyl (e.g., methyl or ethyl) substituted with an —OR 15 group, wherein R 15 is HO-alkyl- (e.g., HO—CH 2 —, or HO—(CH 2 ) 2 —), and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is HO-alkyl- (e.g., HO—CH 2 —, or HO—(CH 2 ) 2 —), and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 is HO-alkyl- (e.g., HO—CH 2 —, or HO—(CH 2 ) 2 —), and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is HO—CH 2 —, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 HO—CH 2 —, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is methyl substituted with an —OR 15 group, wherein R 15 is HO—(CH 2 ) 2 —, and the other of said R 3 or R 4 is H.

In another embodiment, G is —C(R 3 )(R 4 )—, and one of R 3 or R 4 is ethyl substituted with an —OR 15 group, wherein R 15 is HO—(CH 2 ) 2 —, and the other of said R 3 or R 4 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, and R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine).

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), R 6 is H or alkyl (and in one example H), and R 7 is aryl (e.g., phenyl) or aryl (e.g., phenyl) substituted with 1-5 independently selected R 21 groups.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), R 6 is H, and R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected R 21 groups.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), R 6 is H, and R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected halo groups (i.e., the R 21 groups are halo).

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is independently selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), aryl (e.g., phenyl), and aryl (e.g., phenyl) substituted with 1-5 independently selected R 21 groups.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is independently selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo).

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon R 3 and R 4 are each independently selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo).

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo).

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo), and R 6 and R 7 are each H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-5 independently selected halo groups (i.e., the R 21 groups are halo), R 6 is H or alkyl, and R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected R 21 groups.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-5 independently selected halo groups (i.e., the R 21 groups are halo), R 6 is H or alkyl, and R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected halo groups (i.e., the R 21 groups are halo).

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), R 6 is H or alkyl (and in one example H), R 7 is aryl (e.g., phenyl) or aryl (e.g., phenyl) substituted with 1-5 independently selected R 21 groups, and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), R 6 is H, R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected R 21 groups, and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is H, W is O, U is N, R 1 and R 2 are joined together to form a 5-8 membered (e.g., a 6 membered ring) heterocyclyl ring (such as, for example, piperidine), R 6 is H, R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected halo groups (i.e., the R 21 groups are halo), and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is independently selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), aryl (e.g., phenyl), and aryl (e.g., phenyl) substituted with 1-5 independently selected R 21 groups, and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein each R 3 and R 4 is independently selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo), and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon R 3 and R 4 are each independently selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo), and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo), and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-3 independently selected halo groups (i.e., the R 21 groups are halo), R 6 and R 7 are each H, and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-5 independently selected halo groups (i.e., the R 21 groups are halo), R 6 is H or alkyl, R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected R 21 groups, and R 8 is H.

In another embodiment, G is —(C(R 3 )(R 4 )) 2 — wherein on one carbon R 3 and R 4 are H, and on the other carbon one of R 3 and R 4 is H and the other is selected from the group consisting of H, alkyl (e.g., methyl), —OR 15 (e.g., R 15 is H or alkyl, wherein in one example said —OR 15 is —OH and in another example said —OR 15 is —O-propyl), phenyl, and phenyl substituted with 1-5 independently selected halo groups (i.e., the R 21 groups are halo), R 6 is H or alkyl, R 7 is phenyl or phenyl substituted with 1-3 (e.g., 1 or 2) independently selected halo groups (i.e., the R 21 groups are halo), and R 8 is H.

In another embodiment of this invention is directed to compounds of formula I wherein:

(1) none of the rings described in (i) to (xii) of formula I are formed (that is (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 -G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); (2) U is N; (3) V is a bond; (4) W is O; (5) G is —C(R 3 )(R 4 )—; and (6) all remaining substituents are as described for formula I.

In another embodiment of this invention is directed to compounds of formula I wherein:

(1) none of the rings described in (i) to (xii) of formula I are formed (that is (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); (2) U is N; (3) V is a bond; (4) W is O; (5) G is —C(R 3 )(R 4 )—; (6) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups; and (7) all remaining substituents are as described for formula I.

In another embodiment of this invention is directed to compounds of formula I wherein:

(1) none of the rings described in (i) to (xii) of formula I are formed (that is (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); (2) U is N; (3) V is a bond; (4) W is O; (5) G is —C(R 3 )(R 4 )—; (6) R 2 is selected from the group consisting of H, alkyl, and alkyl substituted with 1 to 5 R 21 groups; (7) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) aryl (e.g., phenyl), (b) aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said aryl is substituted with 1 to 3 halos, (ii) in another example said aryl is substituted with 1 to 3 F, (iii) in another example said aryl is substituted with 3 F, (iv) in another example said aryl is substituted with 2 F, and (v) in another example said aryl is substituted with 1 F), (c) heteroaryl (e.g., thienyl), (d) heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said heteroaryl is substituted with 1 to 3 halos, (ii) in another example said heteroaryl is substituted with 1 to 3 F, and (iii) in another example said heteroaryl is substituted with 1 F), (d) cycloalkyl (e.g., cyclopropyl), (e) cycloalkyl (e.g., cyclopropyl) substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cycloalkyl is substituted with 1 to 3 halos, and (ii) in another example said cycloalkyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl), (g) alkyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said alkyl is substituted with one —OR 15 group, (ii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is H, (iii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl-, (iv) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl- and R 18 is —OH and r is 1, and (v) in another example said alkyl is substituted with one —OR 15 wherein R 15 is HO—CH 2 —, or HO—(CH 2 ) 2 —); and

(8) all other substituents are as described for formula I.

In another embodiment of this invention is directed to compounds of formula I wherein:

(1) none of the rings described in (i) to (xii) of formula I are formed (that is (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); (2) U is N; (3) V is a bond; (4) W is O; (5) G is —C(R 3 )(R 4 )—; (6) R 2 is selected from the group consisting of H, alkyl (e.g., methyl, ethyl and propyl, and in one example propyl), and alkyl (e.g., methyl, ethyl and propyl) substituted with 1 —OH group (and in one example the substituted alkyl is —CH 2 CH 2 CH 2 —OH), (7) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) aryl (e.g., phenyl), (b) aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said aryl is substituted with 1 to 3 halos, (ii) in another example said aryl is substituted with 1 to 3 F, (iii) in another example said aryl is substituted with 3 F, (iv) in another example said aryl is substituted with 2 F, and (v) in another example said aryl is substituted with 1 F), (c) heteroaryl (e.g., thienyl), (d) heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said heteroaryl is substituted with 1 to 3 halos, (ii) in another example said heteroaryl is substituted with 1 to 3 F, and (iii) in another example said heteroaryl is substituted with 1 F), (d) cycloalkyl (e.g., cyclopropyl), (e) cycloalkyl (e.g., cyclopropyl) substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cycloalkyl is substituted with 1 to 3 halos, and (ii) in another example said cycloalkyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl), (g) alkyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said alkyl is substituted with one —OR 15 group, (ii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is H, (iii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl-, (iv) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl- and R 18 is —OH and r is 1, and (v) in another example said alkyl is substituted with one —OR 15 wherein R 15 is HO—CH 2 —, or HO—(CH 2 ) 2 —); and

(8) all other substituents are as described for formula I.

In another embodiment of this invention is directed to compounds of formula I wherein:

(1) none of the rings described in (i) to (xii) of formula I are formed (that is (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); (2) U is N; (3) V is a bond; (4) W is O; (5) G is —C(R 3 )(R 4 )—; (6) R 2 is selected from the group consisting of H, alkyl, and alkyl substituted with 1 to 5 R 21 groups; (7) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(8) all other substituents are as described for formula I.

In another embodiment of this invention is directed to compounds of formula I wherein:

(1) none of the rings described in (i) to (xii) of formula I are formed (that is (a) R 1 and R 2 are not joined together, and (b) R 2 and R 6 are not joined together, and (c) R 1 and R 2 are not joined together, and R 2 and R 6 are not joined together (i.e., R 2 is not joined together with R 1 and R 6 ), and (d) R 6 is not joined together with either R 3 or R 4 (i.e., R 6 and R 3 are not joined together, or R 6 and R 4 are not joined together), and (e) R 6 and R 13 of the —N(R 13 )— G moiety, are not joined together, and (f) R 3 and R 4 of the —C(R 3 )(R 4 )— G moiety are not joined together, and (g) one R 3 and one R 4 on one carbon of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (h) an R 3 and an R 4 on adjacent carbons of the —(C(R 3 )(R 4 )) 2 — G moiety are not joined together, and (i) R 1 and R 2 , and R 6 and either R 3 or R 4 , are not joined together to form the rings described in (ix) above, and (j) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (x) above, and (k) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xi) above, and (l) R 1 and R 2 , and R 3 and R 4 , are not joined together to form the rings described in (xii) above (that is none of the rings described above in (i) to (xii) are formed); (2) U is N; (3) V is a bond; (4) W is O; (5) G is —C(R 3 )(R 4 )—; (6) R 2 is selected from the group consisting of H, alkyl (e.g., methyl, ethyl and propyl, and in one example propyl), and alkyl (e.g., methyl, ethyl and propyl) substituted with 1 —OH group (and in one example the substituted alkyl is —CH 2 CH 2 CH 2 —OH), (7) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(8) all other substituents are as described for formula I.

In another embodiment, G is —C(O)—.

In another embodiment, G is —N(R 13 )—.

In another embodiment, V is a bond.

In another embodiment, V is —O—.

In another embodiment, V is —C(O)—.

In another embodiment, V is —N(R 14 )—.

In another embodiment, R 2 is arylalkyl-.

In another embodiment, R 2 is phenylmethyl-.

In another embodiment, R 2 is (4-alkoxy)phenylmethyl-.

In another embodiment, R 2 is (4-methoxy)phenylmethyl-.

In another embodiment, R 1 is H.

In another embodiment, R 1 is alkyl.

In another embodiment, R 1 is methyl.

In another embodiment, R 1 and R 2 are joined together to form a cyclopentyl ring, which is unsubstituted.

In another embodiment, R 1 and R 2 are joined together to form a cyclopentyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 1 and R 2 are joined together to form a cyclohexyl ring, which is unsubstituted.

In another embodiment, R 1 and R 2 are joined together to form a cyclohexyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —ON, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, U is N, and R 1 and R 2 are joined together to form a piperidinyl ring including the N of U as the nitrogen of said piperidinyl ring, which is unsubstituted.

In another embodiment, U is N, and R 1 and R 2 are joined together to form a piperidinyl ring including the N of U as the nitrogen of said piperidinyl ring, wherein said piperidinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, U is N, and R 1 and R 2 are joined together to form a pyrrolidinyl ring including the N of U as the nitrogen of said pyrrolidinyl ring, which is unsubstituted.

In another embodiment, U is N, and R 1 and R 2 are joined together to form a pyrrolidinyl ring including the N of U as the nitrogen of said pyrrolidinyl ring, wherein said pyrrolidinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —ON, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, U is N, and R 1 and R 2 are joined together to form a piperazinyl ring including the N of U as a nitrogen of said piperazinyl ring, which is unsubstituted.

In another embodiment, U is N, and R 1 and R 2 are joined together to form a piperazinyl ring including the N of U as a nitrogen of said piperazinyl ring, wherein said piperazinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment R 1 and R 2 are joined together to form a ring optionally substituted with 1 to 5 independently selected R 21 substitutents, and said ring is fused with an aryl or heteroaryl ring, and said resulting fused ring is optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a ring substituted with 1 to 5 independently selected R 21 substitutents, and said ring is fused with an aryl or heteroaryl ring, and said resulting fused ring is optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a ring optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a ring.

In another embodiment R 1 and R 2 are joined together to form a heterocyclyl ring optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a heterocyclyl ring substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment U is N, and R 1 and R 2 are joined together to form a heterocyclyl ring optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment U is N, and R 1 and R 2 are joined together to form a heterocyclyl ring substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a ring, and said ring is fused with an aryl or heteroaryl ring, and said resulting fused ring is optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a heterocyclyl ring.

In another embodiment U is N, and R 1 and R 2 are joined together to form a heterocyclyl ring.

In another embodiment R 1 and R 2 are joined together to form a piperidinyl ring optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a piperidinyl ring substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment U is N, and R 1 and R 2 are joined together to form a piperidinyl ring optionally substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment U is N, and R 1 and R 2 are joined together to form a piperidinyl ring substituted with 1 to 5 independently selected R 21 substitutents.

In another embodiment R 1 and R 2 are joined together to form a piperidinyl ring optionally substituted with a ═O moiety.

In another embodiment U is N, and R 1 and R 2 are joined together to form a piperidinyl ring optionally substituted with a ═O moiety.

In another embodiment R 1 and R 2 are joined together to form a piperidinyl.

In another embodiment U is N, and R 1 and R 2 are joined together to form a piperidinyl ring.

In another embodiment R 1 and R 2 are joined together to form a piperidinyl ring substituted with a ═O moiety.

In another embodiment U is N, and R 1 and R 2 are joined together to form a piperidinyl ring substituted with a ═O moiety.

In another embodiment R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (c) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment:

(a) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (b) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (c) said R 2 and R 6 cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )— G moiety, are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (c) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (b) said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein said heterocyclyl moiety is substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said heterocyclyl moiety is optionally substituted with a ═O, and (b) said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein said heterocyclyl moiety is optionally substituted with a ═O.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said heterocyclyl moiety is substituted with a ═O, and (b) said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein said heterocyclyl moiety is substituted with a ═O.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein: (a) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (b) said heterocyclyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein: (a) said heterocyclyl moiety is optionally substituted with a ═O, and (b) said heterocyclyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein said heterocyclyl moiety is optionally substituted with a ═O.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein said heterocyclyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein: (a) said heterocyclyl moiety is substituted with a ═O, and (b) said heterocyclyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein said heterocyclyl moiety is substituted with a ═O.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein: (a) said pyrrolidinyl ring is optionally substituted with 1-5 independently selected R 21 substituents, and (b) said pyrrolidinyl ring is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 pyrrolidinyl ring, wherein said pyrrolidinyl ring is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein: (a) said pyrrolidinyl ring is optionally substituted with a ═O, and (b) said pyrrolidinyl ring is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein said pyrrolidinyl ring is optionally substituted with a ═O.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein said pyrrolidinyl ring is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein: (a) said pyrrolidinyl ring is substituted with a ═O, and (b) said pyrrolidinyl ring is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein said pyrrolidinyl ring is substituted with a═O.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein: (a) said heterocyclyl moiety is substituted with 1-5 independently selected R 21 substituents, and (b) said heterocyclyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 membered heterocyclyl moiety, wherein said heterocyclyl moiety is substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a pyrrolidinyl ring, wherein: (a) said pyrrolidinyl ring is substituted with 1-5 independently selected R 21 substituents, and (b) said pyrrolidinyl ring is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents.

In another embodiment R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5 pyrrolidinyl ring, wherein said pyrrolidinyl ring is substituted with 1-5 independently selected R 21 substituents.

In another embodiment, R 6 is H.

In another embodiment, R 6 is alkyl.

In another embodiment, R 6 is methyl.

In another embodiment, R 7 is aryl.

In another embodiment, R 7 is an unsubstituted phenyl.

In another embodiment, R 7 is a phenyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment, R 7 is unsubstituted naphthyl.

In another embodiment, R 7 is naphthyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment, R 7 is unsubstituted biphenyl.

In another embodiment, R 7 is biphenyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 7 is 3-(1,1′-biphenyl)-yl.

In another embodiment, R 7 is 4-(1,1′-biphenyl)-yl.

In another embodiment, R 6 is H and R 7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 6 is methyl, and R 7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 6 is H, and R 7 is a phenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —ON, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 6 is methyl, and R 7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 2 and R 6 are joined together to form a cyclopentyl ring.

In another embodiment, R 2 and R 6 are joined together to form a cyclopentyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 2 and R 6 are joined together to form a cyclohexyl ring.

In another embodiment, R 2 and R 6 are joined together to form a cyclohexyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, U is N, and R 2 and R 6 are joined together to form a piperidinyl ring including the N of U as the nitrogen of said piperidinyl ring, which is unsubstituted.

In another embodiment, U is N, and R 2 and R 6 are joined together to form a piperidinyl ring including the N of U as the nitrogen of said piperidinyl ring, wherein said piperidinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, U is N, and R 2 and R 6 are joined together to form a pyrrolidinyl ring including the N of U as the nitrogen of said pyrrolidinyl ring, which is unsubstituted.

In another embodiment, U is N, and R 2 and R 6 are joined together to form a pyrrolidinyl ring including the N of U as the nitrogen of said pyrrolidinyl ring, wherein said pyrrolidinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, U is N, and R 2 and R 6 are joined together to form a piperazinyl ring including the N of U as a nitrogen of said piperazinyl ring, which is unsubstituted.

In another embodiment, U is N, and R 2 and R 6 are joined together to form a piperazinyl ring including the N of U as a nitrogen of said piperazinyl ring, wherein said piperazinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 2 and R 6 are joined together to form a morpholinyl ring which is unsubstituted.

In another embodiment, R 2 and R 6 are joined together to form a morpholinyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 2 and R 6 are joined together to form a pyranyl ring which is unsubstituted.

In another embodiment, R 2 and R 6 are joined together to form a pyranyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 2 and R 6 are joined together to form a pyrrolidinyl ring which is unsubstituted.

In another embodiment, R 2 and R 6 are joined together to form a pyrrolidinyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, both (R 1 and R 2 ) and (R 2 and R 6 ) are joined together to form independent cycloalkyl rings.

In another embodiment, both (R 1 and R 2 ) and (R 2 and R 6 ) are joined together to form independent cycloalkyl rings, each of which is independently optionally substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, both (R 1 and R 2 ) and (R 2 and R 6 ) are joined together to form independent heterocyclyl rings.

In another embodiment, both (R 1 and R 2 ) and (R 2 and R 6 ) are joined together to form independent heterocyclyl rings, each of which is independently optionally substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, both (R 1 and R 2 ) and (R 2 and R 6 ) are joined together to form independent cycloalkyl rings.

In another embodiment, both R 1 and R 2 are joined together to form a cycloalkyl ring, and R 2 and R 6 are joined together to form a heterocyclyl ring, each of which is independently optionally substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, both R 1 and R 2 are joined together to form a heterocyclyl ring, and R 2 and R 6 are joined together to form a cycloalkyl ring, each of which is independently optionally substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 7 is 4-fluorophenyl.

In another embodiment R 7 is selected from the group consisting of: (a) aryl substituted with 1-3 R 21 moieties (e.g. phenyl substituted 1-3 halos, such as, 1-3 F), (b) aryl (e.g. phenyl) substituted with —OR 15 wherein R 15 is (i) an alkyl substituted with 1-3 halos (e.g, halos independently selected from the group consisting of F and Cl), or (ii) alkyl, (c) aryl (e.g., phenyl), (d) aryl (e.g. phenyl) substituted with alkyl wherein said alkyl is substituted with 1-3 halos (e.g., F), (e) aryl substituted with aryl (e.g. -phenyl-phenyl), (f) alkyl, (g) heteroaryl (e.g. thienyl or pyridyl), (h) arylalkyl-, and (i) cycloalkyl).

In another embodiment R 7 is selected from the group consisting of: (a) aryl substituted with 1-3 R 21 moieties (e.g. phenyl substituted 1-3 halos, such as, 1-3 F), (b) aryl (e.g. phenyl) substituted with —OR 15 wherein R 15 is (i) an alkyl substituted with 1-3 halos (e.g. F), or (ii) alkyl, (c) aryl (e.g., phenyl), (d) aryl (e.g. phenyl) substituted with alkyl wherein said alkyl is substituted with 1-3 halos (e.g., F), (e) aryl substituted with aryl (e.g. -phenyl-phenyl), (f) alkyl, (g) heteroaryl (e.g. thienyl or pyridyl), (h) arylalkyl-, and (i) cycloalkyl).

In another embodiment R 7 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 moieties wherein at least one R 21 moiety is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ).

In another embodiment R 7 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 moieties wherein at least one R 21 moiety is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 7 is aryl (e.g., phenyl) substituted with 1 to 3 R 21 moieties independently selected from the group consisting of: halo (e.g., F), —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 moiety is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 ) group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 ) group is —Si(CH 3 ) 3 ).

In another embodiment R 7 is aryl (e.g., phenyl) substituted with 1 to 3 R 21 moieties independently selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , and wherein at least one R 21 moiety is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 7 is selected from the group consisting of: (a) aryl substituted with 1-3 R 21 moieties (e.g. phenyl substituted 1-3 halos, such as, 1-3 F), (b) aryl (e.g. phenyl) substituted with —OR 15 wherein R 15 is (i) an alkyl substituted with 1-3 halos (e.g. F), or (ii) alkyl, (c) aryl (e.g., phenyl), (d) aryl (e.g. phenyl) substituted with alkyl wherein said alkyl is substituted with 1-3 halos (e.g., F), (e) aryl substituted with aryl (e.g. -phenyl-phenyl), (f) alkyl, (g) heteroaryl (e.g. thienyl or pyridyl), (h) arylalkyl-, and (i) cycloalkyl).

In another embodiment R 7 is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 moieties wherein at least one R 21 moiety is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ).

In another embodiment, R 7 is a phenyl which is substituted with 1-4 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 moiety is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ).

In another embodiment, R 7 is a phenyl which is substituted with 1-4 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl —SF 5 , and —OSF 5 , and wherein at least one R 21 moiety is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment, R 7 is phenyl which is substituted with 1-3 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 moiety is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 ) group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the

In another embodiment, R 7 is phenyl which is substituted with 1-3 substituents independently selected from the group consisting of halo, alkyl, —ON, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl —SF 5 , and —OSF 5 , and wherein at least one R 21 moiety is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment, R 7 is phenyl substituted with 1-3 halos independently selected from the group consisting of F and Cl. In one example said phenyl is substituted with one F and one Cl.

In another embodiment, R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halos, —SF 5 and —OSF 5 , wherein at least one R 21 group is —SF 5 or —OSF 5 .

In another embodiment, R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, Br, —SF 5 and —OSF 5 .

In another embodiment, R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is phenyl substituted with 1-3 F.

In another embodiment, R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group is —SF 5 or —OSF 5 .

In another embodiment, R 7 is phenyl substituted with one —SF 5 group.

In another embodiment, R 7 is phenyl substituted with two —SF 5 groups.

In another embodiment, R 7 is phenyl substituted with three —SF 5 groups.

In another embodiment, R 7 is phenyl substituted with one —OSF 5 group.

In another embodiment, R 7 is phenyl substituted with two —OSF 5 groups.

In another embodiment, R 7 is phenyl substituted with three —OSF 5 groups.

In another embodiment, R 7 is phenyl substituted with 1 F.

In another embodiment, R 7 is phenyl substituted with 1 F, and also substituted with 1 to 2 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 7 is phenyl substituted with 2 F.

In another embodiment R 7 is phenyl substituted with 3F.

In another embodiment R 7 is p-Cl-phenyl.

In another embodiment R 7 is p-Cl-phenyl substituted with 1 to 2 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is naphthyl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ).

In another embodiment, R 7 is naphthyl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is naphthyl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 group is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 .

In another embodiment, R 7 is naphthyl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is naphthyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, Br, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is naphthyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is naphthyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment, R 7 is naphthyl substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 group is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 .

In another embodiment, R 7 is naphthyl substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one group is —SF 5 or —OSF 5 .

In another embodiment, R 7 is unsubstituted biphenyl.

In another embodiment, R 7 is biphenyl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ).

In another embodiment, R 7 is biphenyl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is biphenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 group is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 .

In another embodiment, R 7 is biphenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is biphenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, Br, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is biphenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is biphenyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 7 is biphenyl which is substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 ) group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 group is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 .

In another embodiment, R 7 is biphenyl which is substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 3-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 3-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 3-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of F, Br, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 3-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 4-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 4-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 4-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of F, Br, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 7 is 4-(1,1′-biphenyl)-yl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 6 is H and R 7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 6 is H and R 7 is a biphenyl optionally substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 6 is methyl, and R 7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 6 is methyl, and R 7 is a biphenyl optionally substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 6 is H, and R 7 is a phenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 6 is H, and R 7 is a phenyl optionally substituted with 1-4 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 and —OSF 5 , wherein at least one R 21 group is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment of this invention, R 6 is H, and R 7 is phenyl substituted with 1 to 3 halos selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

In another embodiment of this invention, R 6 is H, and R 7 is phenyl substituted with 1 to 3 F.

In another embodiment of this invention, R 6 is H, and R 7 is phenyl substituted with 1 F.

In another embodiment of this invention, R 6 is H, and R 7 is phenyl substituted with 2 F.

In another embodiment of this invention, R 6 is H, and R 7 is phenyl substituted with 3 F.

In another embodiment R 6 is alkyl, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 group is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 .

In another embodiment R 6 is alkyl, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with 1-5 independently selected R 21 moieties, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is alkyl substituted with 1-5 independently selected R 21 moieties, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, SF 5 , —OSF 5 and —Si(R 24 ) 3 (and in one example each R 24 is the same or different alkyl, and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 or —Si(CH 2 CH 3 ) 2 CH 3 , and in another example the —Si(R 24 ) 3 group is —Si(CH 3 ) 3 ), and wherein at least one R 21 group is selected from the group consisting of —SF 5 , —OSF 5 and —Si(R 24 ) 3 .

In another embodiment R 6 is alkyl substituted with 1-5 independently selected R 21 moieties, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxyl, alkoxy, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halos, SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with one F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with one F, and one or two groups independently selected from the group consisting of SF 5 and —OSF 5 , wherein at least one —SF 5 or —OSF 5 is present.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with one F, and one or two groups independently selected from the group consisting of SF 5 and —OSF 5 , wherein at least one —SF 5 or —OSF 5 is present.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1 to 3 groups independently selected from the group consisting of SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1 to 2 groups independently selected from the group consisting of SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1 to 3 —SF 5 groups (and in one example one —SF 5 , and in another example two —SF 5 groups, and in another example three —SF 5 groups).

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1 to 3 —OSF 5 groups (and in one example one —OSF 5 , and in another example two —OSF 5 groups, and in another example three —OSF 5 groups).

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 16 , and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 R 21 independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halos, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 16 , and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with one F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with one F, and said phenyl is also subsubstitued with one or two groups independently selected from the group consisting of: —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halos, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of F, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F, and also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halo, alkyl, —ON, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halos, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-2 F, and said phenyl is also substituted with 1 to 2 R 21 groups independently selected from the group consisting of —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 to 3.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two groups selected from the group consisting of —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 R 21 groups independently selected from the group consisting of halos, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-2 F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 to 3.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with one F.

In another embodiment R 6 is alkyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two substituents selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with 1-3 independently selected R 21 moieties, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is methyl substituted with 1-3 independently selected R 21 moieties, and R 7 is phenyl substituted with 1-3 R 21 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 R 21 independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-2 independently selected halos, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or three.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-3 F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with 1-2 F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or three.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with one F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 16 , and R 7 is phenyl substituted with 1-2 independently selected halos, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with 1-2 independently selected F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with one F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, and said R 21 moiety is —OR 15 , and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-2 independently selected halos, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-2 independently selected F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and R 7 is phenyl substituted with 1-3 substituents independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-2 independently selected halos, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-3 F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with 1-2 F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is H, and said R 15 is selected from the group consisting of: H and alkyl, and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl and heteroaryl groups.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH 2 , —NH(alkyl), —N(alkyl) 2 , hydroxy, alkoxy, aryl, heteroaryl, —SF 5 and —OSF 5 , wherein at least one R 21 group on said phenyl is selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 independently selected halos.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-2 independently selected halos, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-3 independently selected F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with 1-2 independently selected F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 , and wherein the total number of substituents on said phenyl is 2 or 3.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with one F.

In another embodiment R 6 is methyl substituted with one R 21 moiety, said R 21 moiety is —OR 15 , and said R 15 is alkyl (e.g. methyl), and R 7 is phenyl substituted with one F, and said phenyl is also substituted with one or two groups independently selected from the group consisting of —SF 5 and —OSF 5 .

In another embodiment, R 8 is selected from the group consisting of H, halo (e.g., F), alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, with each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- being optionally substituted with 1-3 independently selected R 21 substituents.

In another embodiment R 8 is halo.

In another embodiment R 8 is F.

In another embodiment, R 8 is H.

In another embodiment, R 8 is alkyl.

In another embodiment, R 8 is methyl.

In another embodiment, R 10 is aryl.

In another embodiment, R 10 is phenyl.

In another embodiment R 10 is aryl substituted with 1 halo.

In another embodiment R 10 is aryl substituted with 1 halo, and said halo is F.

In another embodiment R 10 is aryl substituted with 1 to 3 independently selected R 21 moieties.

In another embodiment R 10 is aryl substituted with 1 to 3 R 21 moieties, wherein each R 21 moiety is the same or different —OR 18 group.

In another embodiment R 10 is aryl substituted with 1 R 21 moiety.

In another embodiment R 10 is phenyl substituted with 1 halo.

In another embodiment R 10 is phenyl substituted with 1 halo, and said halo is F.

In another embodiment R 10 is 3-halo-phenyl:

(wherein the bond from the carbon labeled as 4 is to the R 9 group).

In another embodiment R 10 is 3-F-phenyl:

(wherein the bond from the carbon labeled as 4 is to the R 9 group).

In another embodiment R 10 is aryl substituted with one —OR 15 group.

In another embodiment R 10 is aryl substituted with one —OR 15 group, and said R 15 is alkyl (e.g., methyl).

In another embodiment R 10 is phenyl substituted with 1 to 3 independently selected R 21 moieties.

In another embodiment R 10 is phenyl substituted with 1 to 3 R 21 moieties, wherein each R 21 moiety is the same or different —OR 15 group.

In another embodiment R 10 is phenyl substituted with 1 R 21 moiety.

In another embodiment R 10 is phenyl substituted with one —OR 15 group.

In another embodiment R 10 is phenyl substituted with one —OR 15 group, and said R 15 is alkyl (e.g., methyl).

In another embodiment R 10 is 3-OR 15 -phenyl:

(wherein the bond from the carbon labeled as 4 is to the R 9 group).

In another embodiment R 10 is 3-OR 15 -phenyl:

wherein R 15 is alkyl (wherein the bond from the carbon labeled as 4 is to the R 9 group).

In another embodiment R 10 is 3-OR 15 -phenyl:

wherein R 15 is methyl (i.e., R 10 is 3-methoxy-phenyl).

In another embodiment, R 10 is heteroaryl.

In another embodiment, R 10 is unsubstituted heteroaryl.

In another embodiment R 10 is unsubstituted heteroaryl wherein said heteroaryl is pyridyl.

In another embodiment R 10 is:

In another embodiment R 10 is:

wherein the —R 10 —R 9 moiety is:

In another embodiment R 10 is aryl substituted with 1 to 3 R 21 moieties, wherein each R 21 moiety is the same or different halo.

In another embodiment R 10 is aryl substituted with 1 to 3 R 21 moieties, wherein each R 21 moiety is F.

In another embodiment R 10 is aryl substituted with one R 21 moiety, and said R 21 moiety is halo.

In another embodiment R 10 is aryl substituted with one R 21 moiety, said R 21 moiety is -halo, and said halo is F.

In another embodiment R 10 is phenyl substituted with 1 to 3 R 21 moieties, wherein each R 21 moiety is the same or different halo.

In another embodiment R 10 is phenyl substituted with 1 to 3 R 21 moieties, wherein each R 21 moiety is F.

In another embodiment R 10 is selected from the group consisting of:

In another embodiment of this invention, R 9 is selected from the group consisting of alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each R 9 group is optionally substituted with 1-3 independently selected R 21 substituents.

In another embodiment of this invention R 9 is selected from the group consisting of heteroaryl and heteroaryl substituted with 1-3 R 21 groups, and wherein each R 21 is independently selected.

In another embodiment, R 9 is unsubstituted heteroaryl.

In another embodiment, R 9 is heteroaryl which is substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, CN, NH 2 , NH(alkyl), N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment, R 9 is heteroaryl substituted with 1 to 3 independently selected alkyl groups.

In another embodiment, R 9 is heteroaryl substituted with one is alkyl group (e.g., methyl).

In another embodiment of this invention R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with 1-3 R 21 groups, and wherein each R 21 is independently selected.

In another embodiment of this invention R 9 is imidazolyl substituted with 1-3 R 21 groups, and wherein each R 21 is independently selected.

In another embodiment, R 9 is imidazolyl substituted with 1-3 substituents independently selected from the group consisting of halo, alkyl, CN, NH 2 , NH(alkyl), N(alkyl) 2 , hydroxy and alkoxy groups.

In another embodiment of this invention R 9 is selected from the group consisting of:

In another embodiment of this invention R 9 is selected from the group consisting of:

In another embodiment of this invention R 9 is 1 g. In another embodiment of this invention R 9 is:

(i.e. 2g). In another embodiment of this invention R 9 is 3g. In another embodiment of this invention R 9 is 4g. In another embodiment of this invention R 9 is 5g. In another embodiment of this invention R 9 is 6g. In another embodiment of this invention R 9 is 7g. In another embodiment of this invention R 9 is 8g. In another embodiment of this invention R 9 is 9g. In another embodiment of this invention R 9 is 10g. In another embodiment of this invention R 9 is 11g. In another embodiment of this invention R 9 is 12g. In another embodiment of this invention R 9 is 13g. In another embodiment of this invention R 9 is 14g. In another embodiment of this invention R 9 is 15g. In another embodiment of this invention R 9 is 16g. In another embodiment of this invention R 9 is 17g. In another embodiment of this invention R 9 is 18g. In another embodiment of this invention R 9 is 19g. In another embodiment of this invention R 9 is 20g. In another embodiment of this invention R 9 is 21g. In another embodiment of this invention R 9 is 22g. In another embodiment of this invention R 9 is 23g. In another embodiment of this invention R 9 is 24g. In another embodiment of this invention R 9 is 25g. In another embodiment of this invention R 9 is 26g. In another embodiment of this invention R 9 is 27g. In another embodiment of this invention R 9 is 28g. In another embodiment of this invention R 9 is 29g. In another embodiment of this invention R 9 is 30g. In another embodiment of this invention R 9 is 31g. In another embodiment of this invention R 9 is 32g. In another embodiment of this invention R 9 is 33g. In another embodiment of this invention R 9 is 34g. In another embodiment of this invention R 9 is 35g. In another embodiment of this invention R 9 is 36g. In another embodiment of this invention R 9 is 37g. In another embodiment of this invention R 9 is 38g. In another embodiment of this invention R 9 is 39g. In another embodiment of this invention R 9 is 40g. In another embodiment of this invention R 9 is 41g. In another embodiment of this invention R 9 is 42g. In another embodiment of this invention R 9 is 43g. In another embodiment of this invention R 9 is 44g. In another embodiment of this invention R 9 is 45g. In another embodiment of this invention R 9 is 46g. In another embodiment of this invention R 9 is 47g. In another embodiment of this invention R 9 is 48g. In another embodiment of this invention R 9 is 49g. In another embodiment of this invention R 9 is 50g. In another embodiment of this invention R 9 is 51g. In another embodiment of this invention R 9 is 52g.

In another embodiment, R 9 is imidazol-1-yl.

In another embodiment, R 9 is 4-methyl-imidazol-1-yl:

In another embodiment, R 9 is 5-chloro-4-methyl-imidazol-1-yl.

In another embodiment R 10 is selected from the group consisting of aryl and aryl substituted with one or more R 21 groups, and R 9 is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more R 21 groups, and wherein each R 21 is independently selected.

In another embodiment R 10 is selected from the group consisting of phenyl and phenyl substituted with 1-3 independently selected R 21 groups, and R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with 1-3 independently selected R 21 groups.

In another embodiment R 10 is phenyl substituted with 1-3 independently selected R 21 groups, and R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with 1-3 independently selected R 21 groups.

In another embodiment R 10 is selected from the group consisting of heteroaryl and heteroaryl substituted with 1-3 R 21 groups, and the R 9 group is selected from the group consisting of heteroaryl and heteroaryl substituted with 1-3 R 21 groups, and wherein each R 21 is independently selected.

In another embodiment R 10 is selected from the group consisting of pyridyl and pyridyl substituted with 1-3 R 21 groups, and the R 9 group is selected from the group consisting of imidazolyl and imidazolyl substituted with 1-3 R 21 groups, and wherein each R 21 is independently selected.

In another embodiment R 10 is pyridyl, and the R 9 group is imidazolyl substituted with 1-3 R 21 groups, and wherein each R 21 is independently selected.

In another embodiment of this invention R 10 is selected from the group consisting of 1A to 55A, and R 9 is selected from the group consisting of 1 g to 52g.

In another embodiment of this invention R 10 is selected from the group consisting of 1A to 42A, and R 9 is selected from the group consisting of 1 g to 13g.

In another embodiment of this invention R 10 is selected from the group consisting of 1A to 55A, and R 9 is 2g.

In another embodiment of this invention R 10 is selected from the group consisting of 1A to 55A, and R 9 is H.

In another embodiment of this invention R 10 is selected from the group consisting of 1A to 42A, and R 9 is 2g.

In another embodiment of this invention R 10 is selected from the group consisting of 1A to 42A, and R 9 is H.

In another embodiment of this invention the R 10 —R 9 — moiety is selected from the group consisting of:

In another embodiment the R 10 —R 9 — moiety is 1b. In another embodiment the R 10 —R 9 — moiety is 2b. In another embodiment the R 10 —R 9 — moiety is 3b. In another embodiment the R 10 —R 9 — moiety is 4b. In another embodiment the R 10 —R 9 -moiety is 5b. In another embodiment the R 10 —R 9 — moiety is 6b. In another embodiment the R 10 —R 9 — moiety is 7b. In another embodiment the R 10 —R 9 — moiety is 8b. In another embodiment the R 10 —R 9 — moiety is 9b. In another embodiment the R 10 —R 9 — moiety is 10b. In another embodiment the R 10 —R 9 — moiety is 11b. In another embodiment the R 10 —R 9 — moiety is 12b. In another embodiment the R 10 —R 9 — moiety is 13b. In another embodiment the R 10 —R 9 — moiety is 14b. In another embodiment the R 10 —R 9 — moiety is 15b. In another embodiment the R 10 —R 9 — moiety is 16b. In another embodiment the R 10 —R 9 — moiety is 17b. In another embodiment the R 10 —R 9 — moiety is 18b. In another embodiment the R 10 —R 9 — moiety is 19b. In another embodiment the R 10 —R 9 — moiety is 20b. In another embodiment the R 10 —R 9 — moiety is 21b. In another embodiment the R 10 —R 9 — moiety is 22b. In another embodiment the R 10 —R 9 — moiety is 23b. In another embodiment the R 10 —R 9 — moiety is 24b. In another embodiment the R 10 —R 9 — moiety is 25b. In another embodiment the R 10 —R 9 — moiety is 26b. In another embodiment the R 10 —R 9 — moiety is 27b. In another embodiment the R 10 —R 9 — moiety is 28b. In another embodiment the R 10 —R 9 — moiety is 29b. In another embodiment the R 10 —R 9 — moiety is 30b. In another embodiment the R 10 —R 9 — moiety is 31b. In another embodiment the R 10 —R 9 — moiety is 32b. In another embodiment the R 10 —R 9 — moiety is 33b. In another embodiment the R 10 —R 9 — moiety is 34b. In another embodiment the R 10 —R 9 — moiety is 35b. In another embodiment the R 10 —R 9 — moiety is 36b. In another embodiment the R 10 —R 9 — moiety is 37b. In another embodiment the R 10 —R 9 — moiety is 38b. In another embodiment the R 10 —R 9 — moiety is 39b. In another embodiment the R 10 —R 9 — moiety is 40b. In another embodiment the R 10 —R 9 — moiety is 41b. In another embodiment the R 10 —R 9 — moiety is 42b. In another embodiment the R 10 —R 9 — moiety is 43b. In another embodiment the R 10 —R 9 — moiety is 44b. In another embodiment the R 10 —R 9 — moiety is 45b. In another embodiment the R 10 —R 9 — moiety is 46b. In another embodiment the R 10 —R 9 — moiety is 47b. In another embodiment the R 10 —R 9 — moiety is 48b. In another embodiment the R 10 —R 9 — moiety is 49b. In another embodiment the R 10 —R 9 — moiety is 50b. In another embodiment the R 10 —R 9 — moiety is 51b. In another embodiment the R 10 —R 9 — moiety is 52b. In another embodiment the R 10 —R 9 — moiety is 53b.

In another embodiment the R 9 —R 10 — moiety is:

In another embodiment the R 9 —R 10 — moiety is:

In another embodiment the R 9 —R 10 — moiety is:

In another embodiment the R 9 —R 10 — moiety is:

In another embodiment the R 9 —R 10 — moiety is:

In another embodiment R 9 —R 10 — moiety is:

In another embodiment R 9 —R 10 — moiety is:

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof): wherein:

either

(i) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; or (ii) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; or (iii) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and

U is CH;

V is selected from the group consisting of a bond, —O—, and —N(R 14 )—;

R 1 (when R 1 is not joined to R 2 ), R 2 (when R 2 is not joined to R 1 or R 6 ), R 3 , R 4 , R 5 , R 6 (when R 6 is not joined to R 2 ), R 7 , R 11 and R 12 are each independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, and wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents; and

all other substituents are as defined for formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof): wherein:

either

(i) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (ii) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (iii)

(a) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C 4 -C 8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (3) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (4) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (b) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C 4 -C 8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (3) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (4) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (c) said R 2 and R 6 cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or

(iv) R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )— G moiety, are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (v) R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (c) said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; and

U is CH; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

either

(i) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; or (ii) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; or (iii) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein each of said cycloalkyl, cycloalkenyl, heterocyclyl, or heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and

U is N;

V is selected from the group consisting of a bond, —O—, and —N(R 14 )—;

R 1 (when R 1 is not joined to R 2 ), R 2 (when R 2 is not joined to R 1 or R 6 ), R 3 , R 4 , R 5 , R 6 (when R 6 is not joined to R 2 ), R 7 , R 11 and R 12 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

either

(i) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (ii) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (iii)

(a) R 1 and R 2 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (3) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (4) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (b) R 2 and R 6 are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (1) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (2) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (3) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (4) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents; and (c) said R 2 and R 6 cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or

(iv) R 6 and either R 3 or R 4 of the —C(R 3 )(R 4 )— G moiety, are joined together to form a C4-C8 cycloalkyl, C4-C8 cycloalkenyl, 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said cycloalkyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (c) said cycloalkenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (d) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (e) said cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; or (v) R 6 and R 13 of the —N(R 13 )— G moiety, are joined together to form a 5-8 membered heterocyclyl or 5-8 membered heterocyclenyl moiety, wherein: (a) said heterocyclyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, (b) said heterocyclenyl moiety is optionally substituted with 1-5 independently selected R 21 substituents, and (c) said heterocyclyl or heterocyclenyl moiety is optionally fused with an aryl or heteroaryl ring, and the ring moiety resulting from the fusion is optionally substituted with 1-5 independently selected R 21 substituents; and

U is N; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 is H;

R 2 and R 6 are connected to form a 4-7 membered cycloalkyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 6 is H;

R 1 and R 2 are connected to form a 4-7 membered cycloalkyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 is H;

R 2 and R 6 are connected to form a 5-8 membered heterocyclyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl; and

R 5 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 6 is H;

R 1 and R 2 are connected to form a 5-8 membered heterocyclyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a 5-8 membered heterocyclyl ring;

R 2 and R 6 are connected to form a 5-8 membered heterocyclyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 2 and R 6 are connected to form a 4-7 membered cycloalkyl ring;

R 1 and R 2 are connected to form a 4-7 membered cycloalkyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a piperidinyl ring;

R 2 and R 6 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is N;

R 1 and R 2 are connected to form a piperazinyl ring;

R 2 and R 6 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a piperidinyl ring;

R 2 and R 6 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a piperazinyl ring;

R 2 and R 6 are connected to form a piperidnyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroaryl alkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a cyclohexyl ring;

R 2 and R 6 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a cyclohexyl ring;

R 2 and R 6 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a piperidinyl ring;

R 2 and R 6 are connected to form a cyclohexyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a piperazinyl ring;

R 2 and R 6 are connected to form a cyclohexyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 6 is H;

R 1 and R 2 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 5 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 6 is H;

R 1 and R 2 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 5 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 is H;

R 6 and R 2 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyl alkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 is H;

R 6 and R 2 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is phenyl;

R 9 is imidazol-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 is H;

R 2 and R 6 are connected to form a 4-7 membered cycloalkyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 6 is H;

R 1 and R 2 are connected to form a 4-7 membered cycloalkyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 is H;

R 2 and R 6 are connected to form a 5-8 membered heterocyclyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally isubstituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 6 is H;

R 1 and R 2 are connected to form a 5-8 membered heterocyclyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a 5-8 membered heterocyclyl ring;

R 2 and R 6 are connected to form a 5-8 membered heterocyclyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 2 and R 6 are connected to form a 4-7 membered cycloalkyl ring;

R 1 and R 2 are connected to form a 4-7 membered cycloalkyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 5 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 16 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a piperidinyl ring;

R 2 and R 6 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is N;

R 1 and R 2 are connected to form a piperazinyl ring;

R 2 and R 6 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a piperidinyl ring;

R 2 and R 6 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 and R 2 are connected to form a piperazinyl ring;

R 2 and R 6 are connected to form a piperidnyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a cyclohexyl ring;

R 2 and R 6 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a cyclohexyl ring;

R 2 and R 6 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a piperidinyl ring;

R 2 and R 6 are connected to form a cyclohexyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 );

R 1 and R 2 are connected to form a piperazinyl ring;

R 2 and R 6 are connected to form a cyclohexyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos). Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 6 is H;

R 1 and R 2 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 6 is H;

R 1 and R 2 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 is H;

R 6 and R 2 are connected to form a piperidinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I (or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof):

wherein:

U is C(R 5 ) or N;

R 1 is H;

R 6 and R 2 are connected to form a piperazinyl ring;

R 7 is 3-(1,1′-biphenyl)-yl;

R 8 is H;

R 5 is selected from the group consisting of H, alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclylalkyl- is optionally substituted with 1-5 independently selected R 21 substituents;

R 10 is selected from the group consisting of: 3-methoxy-phenyl and 3-F-phenyl (and in one example R 10 is 3-methoxy-phenyl, and in another example R 10 is 3-F-phenyl);

R 9 is 4-methyl-imidazolyl-1-yl; and

all other substituents are as defined in formula I (including the provisos).

Another embodiment of this invention is directed to compounds of formula I selected from the group consisting of:

wherein all substituents are as defined for formula I.

Representative compounds of this invention include compounds 1 to 117 (identified in the methods below), the final compound of Method T and the final compound of Method U.

Another embodiment of this invention is directed to compound Z1

Another embodiment of this invention is directed to compound Z2.

Another embodiment of this invention is directed to compound Z3.

Another embodiment of this invention is directed to compound Z4.

Another embodiment of this invention is directed to compound Z5.

Another embodiment of this invention is directed to compound Z6.

Another embodiment of this invention is directed to compound Z7.

Another embodiment of this invention is directed to compound Z8.

Another embodiment of this invention is directed to compound Z9.

Another embodiment of this invention is directed to compound Z10.

Another embodiment of this invention is directed to compound Z11.

Another embodiment of this invention is directed to compound Z12.

Another embodiment of this invention is directed to compound Z13.

Another embodiment of this invention is directed to compound Z14.

Another embodiment of this invention is directed to compound Z15.

Another embodiment of this invention is directed to compound Z16.

Another embodiment of this invention is directed to compound Z17.

Another embodiment of this invention is directed to compound Z18.

Another embodiment of this invention is directed to compound Z19.

Another embodiment of this invention is directed to compound Z20.

Another embodiment of this invention is directed to compound Z21.

Another embodiment of this invention is directed to compound Z22.

Another embodiment of this invention is directed to compound Z23.

Another embodiment of this invention is directed to compound Z24.

Another embodiment of this invention is directed to compound 1.

Another embodiment of this invention is directed to compound 2.

Another embodiment of this invention is directed to compound 3.

Another embodiment of this invention is directed to compound 4.

Another embodiment of this invention is directed to compound 5.

Another embodiment of this invention is directed to compound 6.

Another embodiment of this invention is directed to compound 7.

Another embodiment of this invention is directed to compound 8.

Another embodiment of this invention is directed to compound 9.

Another embodiment of this invention is directed to compound 10.

Another embodiment of this invention is directed to compound 11.

Another embodiment of this invention is directed to compound 12.

Another embodiment of this invention is directed to compound 13.

Another embodiment of this invention is directed to compound 14.

Another embodiment of this invention is directed to compound 15.

Another embodiment of this invention is directed to compound 16.

Another embodiment of this invention is directed to compound 17.

Another embodiment of this invention is directed to compound 18.

Another embodiment of this invention is directed to compound 19.

Another embodiment of this invention is directed to compound 20.

Another embodiment of this invention is directed to compound 21.

Another embodiment of this invention is directed to compound 22.

Another embodiment of this invention is directed to compound 23.

Another embodiment of this invention is directed to compound 24.

Another embodiment of this invention is directed to compound 25.

Another embodiment of this invention is directed to compound 26.

Another embodiment of this invention is directed to compound 27.

Another embodiment of this invention is directed to compound 28.

Another embodiment of this invention is directed to compound 29.

Another embodiment of this invention is directed to compound 30.

Another embodiment of this invention is directed to compound 31.

Another embodiment of this invention is directed to compound 32.

Another embodiment of this invention is directed to compound 33.

Another embodiment of this invention is directed to compound 34.

Another embodiment of this invention is directed to compound 35.

Another embodiment of this invention is directed to compound 36.

Another embodiment of this invention is directed to compound 37.

Another embodiment of this invention is directed to compound 38.

Another embodiment of this invention is directed to compound 39.

Another embodiment of this invention is directed to compound 40.

Another embodiment of this invention is directed to compound 41.

Another embodiment of this invention is directed to compound 42.

Another embodiment of this invention is directed to compound 43.

Another embodiment of this invention is directed to compound 44.

Another embodiment of this invention is directed to compound 45.

Another embodiment of this invention is directed to compound 46.

Another embodiment of this invention is directed to compound 47.

Another embodiment of this invention is directed to compound 50.

Another embodiment of this invention is directed to compound 51.

Another embodiment of this invention is directed to compound 52.

Another embodiment of this invention is directed to compound 53.

Another embodiment of this invention is directed to compound 54.

Another embodiment of this invention is directed to compound 55.

Another embodiment of this invention is directed to compound 56.

Another embodiment of this invention is directed to compound 57.

Another embodiment of this invention is directed to compound 58.

Another embodiment of this invention is directed to compound 59.

Another embodiment of this invention is directed to compound 60.

Another embodiment of this invention is directed to compound 61.

Another embodiment of this invention is directed to compound 62.

Another embodiment of this invention is directed to compound 63.

Another embodiment of this invention is directed to compound 64.

Another embodiment of this invention is directed to compound 65.

Another embodiment of this invention is directed to compound 66.

Another embodiment of this invention is directed to compound 67.

Another embodiment of this invention is directed to compound 68.

Another embodiment of this invention is directed to compound 69.

Another embodiment of this invention is directed to compound 70.

Another embodiment of this invention is directed to compound 71.

Another embodiment of this invention is directed to compound 72.

Another embodiment of this invention is directed to compound 73.

Another embodiment of this invention is directed to compound 74.

Another embodiment of this invention is directed to compound 75.

Another embodiment of this invention is directed to compound 76.

Another embodiment of this invention is directed to compound 77.

Another embodiment of this invention is directed to compound 78.

Another embodiment of this invention is directed to compound 79.

Another embodiment of this invention is directed to compound 80.

Another embodiment of this invention is directed to compound 81.

Another embodiment of this invention is directed to compound 82.

Another embodiment of this invention is directed to compound 83.

Another embodiment of this invention is directed to compound 84.

Another embodiment of this invention is directed to compound 85.

Another embodiment of this invention is directed to compound 86.

Another embodiment of this invention is directed to compound 87.

Another embodiment of this invention is directed to compound 88.

Another embodiment of this invention is directed to compound 89.

Another embodiment of this invention is directed to compound 90.

Another embodiment of this invention is directed to compound 91.

Another embodiment of this invention is directed to compound 92.

Another embodiment of this invention is directed to compound 93.

Another embodiment of this invention is directed to compound 94.

Another embodiment of this invention is directed to compound 95.

Another embodiment of this invention is directed to compound 96.

Another embodiment of this invention is directed to compound 97.

Another embodiment of this invention is directed to compound 98.

Another embodiment of this invention is directed to compound 99.

Another embodiment of this invention is directed to compound 100.

Another embodiment of this invention is directed to compound 101.

Another embodiment of this invention is directed to compound 102.

Another embodiment of this invention is directed to compound 103.

Another embodiment of this invention is directed to compound 104.

Another embodiment of this invention is directed to compound 105.

Another embodiment of this invention is directed to compound 106.

Another embodiment of this invention is directed to compound 107.

Another embodiment of this invention is directed to compound 108.

Another embodiment of this invention is directed to compound 109.

Another embodiment of this invention is directed to compound 110.

Another embodiment of this invention is directed to compound 111.

Another embodiment of this invention is directed to compound 112.

Another embodiment of this invention is directed to compound 113.

Another embodiment of this invention is directed to compound 114.

Another embodiment of this invention is directed to compound 115.

Another embodiment of this invention is directed to compound 116.

Another embodiment of this invention is directed to compound 117.

Another embodiment of this invention is directed to the final compound of Method T.

Another embodiment of this invention is directed to the final compound of Method U.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, and R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 3 , R 4 and R 8 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 3 , R 4 and R 8 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 3 , R 4 and R 8 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, R 3 , R 4 and R 8 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, R 3 , R 4 and R 8 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, R 3 , R 4 and R 8 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z1 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 3 , R 4 , R 6 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, and R 3 , R 4 , R 6 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 3 and R 4 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 3 and R 4 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 3 and R 4 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, R 3 and R 4 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, R 3 and R 4 are as defined for formula I, R 6 is H, and R 7 is a phenyl) substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, R 3 and R 4 are as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 F.

Another embodiment of this invention is directed to a compound of formula I having the formula Z2 wherein the R 9 —R 10 — group is 50b, each R 3 and each R 4 is H, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 halos independently selected from the group consisting of Cl and F. In one example said phenyl is substituted with one Cl and one F.

Other embodiments of this invention are directed to any one of the above embodiments directed to Z1 wherein R 7 is a phenyl substituted with an —SF 5 group, or an —OSF 5 group (e.g., p-SF 5 -phenyl, or p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 16 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein the R 9 —R 10 — group is 50b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z3 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein the R 9 —R 10 — group is 50b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z4 wherein the R 9 —R 10 — group is 50b, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z5 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z5 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 16 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z5 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z5 wherein the R 9 —R 10 — group is 50b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z5 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z5 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein the R 9 —R 10 — group is 50b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl),

Another embodiment of this invention is directed to a compound of formula I having the formula Z6 wherein the R 9 —R 10 — group is 50b, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula having the formula Z7 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z7 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z7 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z7 wherein the R 9 —R 10 — group is 50b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z7 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z7 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z7 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, R 6 is H, R′ is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein the R 9 —R 10 — group is 50b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z8 wherein the R 9 —R 10 — group is 50b, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 16 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 16 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein the R 9 —R 10 — group is 50b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z9 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein the R 9 —R 10 — group is 50b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z10 wherein the R 9 —R 10 — group is 50b, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl).

In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein the R 9 —R 10 — group is 50b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl).

In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z11 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein the R 9 —R 10 — group is 50b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z12 wherein the R 9 —R 10 — group is 50b, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein the R 9 —R 10 — group is 50b, and R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 8 is as defined for formula I, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z13 wherein the R 9 —R 10 — group is 50b, R 8 is as defined for formula I, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 , In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein the R 9 —R 10 — group is 50b, and R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of halo (e.g., F), —SF 5 , and —OSF 5 .

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, R 6 is H, and R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl). In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z14 wherein the R 9 —R 10 — group is 50b, R 6 is H, R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of F, —SF 5 , and —OSF 5 . In one example R 7 is phenyl substituted with 1 to 3 F. In another example R 7 is phenyl substituted with one —SF 5 group (e.g., R 7 is p-SF 5 -phenyl).

In another example R 7 is phenyl substituted with one —OSF 5 group (e.g., R 7 is p-OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z15 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z15 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z15 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z15 wherein the R 9 —R 10 — group is 50b, and R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z15 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, one of R 3 and R 4 is H and the remaining R 3 or R 4 is selected from the group consisting of: H and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , R 8 is as defined for formula I, R 6 is H, and R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , provided that if both R 3 and R 4 are H, then R 7 is not H (that is when R 3 and R 4 are both H, then R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ) In one example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 or —OSF 5 . In another example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 (e.g., the R 3 or R 4 substituent is -p-SF 5 -phenyl. In another example R 3 and R 4 are H, and R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 (and (i) in one example R 7 is phenyl substituted with an —SF 5 group (e.g., p-SF 5 -phenyl), (ii) in another example R 7 is phenyl substituted with an —OSF 5 group (e.g., p—OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z15 wherein the R 9 —R 10 — group is 50b, one of R 3 and R 4 is H and the remaining R 3 or R 4 is selected from the group consisting of: H and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , R 8 is as defined for formula I, R 6 is H, and R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , provided that if both R 3 and R 4 are H, then R 7 is not H (that is when R 3 and R 4 are both H, then R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ). In one example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 or —OSF 5 . In another example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 (e.g., the R 3 or R 4 substituent is -p-SF 5 -phenyl. In another example R 3 and R 4 are H, and R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 (and (i) in one example R 7 is phenyl substituted with an —SF 5 group (e.g., p-SF 5 -phenyl), (ii) in another example R 7 is phenyl substituted with an —OSF 5 group (e.g., p—OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z16 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z16 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 16 is selected from the group consisting of 1A to 55A, and R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z16 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z16 wherein the R 9 —R 10 — group is 50b, and R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula having the formula Z16 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, one of R 3 and R 4 is H and the remaining R 3 or R 4 is selected from the group consisting of: H and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , R 6 is H, and R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , provided that if both R 3 and R 4 are H, then R 7 is not H (that is when R 3 and R 4 are both H, then R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ). In one example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 or —OSF 5 . In another example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 (e.g., the R 3 or R 4 substituent is -p-SF 5 -phenyl. In another example R 3 and R 4 are H, and R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 (and (i) in one example R 7 is phenyl substituted with an —SF 5 group (e.g., p-SF 5 -phenyl), (ii) in another example R 7 is phenyl substituted with an —OSF 5 group (e.g., p—OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z16 wherein the R 9 —R 10 — group is 50b, one of R 3 and R 4 is H and the remaining R 3 or R 4 is selected from the group consisting of: H and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , R 6 is H, and R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 , provided that if both R 3 and R 4 are H, then R 7 is not H (that is when R 3 and R 4 are both H, then R 7 is a phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ). In one example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 or —OSF 5 . In another example, R 7 is H and one of R 3 or R 4 is phenyl substituted with —SF 5 (e.g., the R 3 or R 4 substituent is -p-SF 5 -phenyl. In another example R 3 and R 4 are H, and R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 (and (i) in one example R 7 is phenyl substituted with an —SF 5 group (e.g., p-SF 5 -phenyl), (ii) in another example R 7 is phenyl substituted with an —OSF 5 group (e.g., p—OSF 5 -phenyl).

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein the R 9 —R 10 — group is 50b, and V, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) aryl (e.g., phenyl), (b) aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said aryl is substituted with 1 to 3 halos, (ii) in another example said aryl is substituted with 1 to 3 F, (iii) in another example said aryl is substituted with 3 F, (iv) in another example said aryl is substituted with 2 F, and (v) in another example said aryl is substituted with 1 F), (c) heteroaryl (e.g., thienyl), (d) heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said heteroaryl is substituted with 1 to 3 halos, (ii) in another example said heteroaryl is substituted with 1 to 3 F, and (iii) in another example said heteroaryl is substituted with 1 F), (d) cycloalkyl (e.g., cyclopropyl), (e) cycloalkyl (e.g., cyclopropyl) substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cycloalkyl is substituted with 1 to 3 halos, and (ii) in another example said cycloalkyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl), (g) alkyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said alkyl is substituted with one —OR 15 group, (ii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is H, (iii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl-, (iv) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl- and R 18 is —OH and r is 1, and (v) in another example said alkyl is substituted with one —OR 15 wherein R 15 is HO—CH 2 —, or HO—(CH 2 ) 2 —); and

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(6) R 8 is as defined for formula I;

(7) R 1 is as defined for formula I;

(8) V is a bond; and

(9) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(6) R 8 is as defined for formula I;

(7) R 1 is as defined for formula I;

(8) V is a bond; and

(9) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of H, alkyl (e.g., methyl, ethyl and propyl, and in one example propyl), and alkyl (e.g., methyl, ethyl and propyl) substituted with 1 —OH group (and in one example the substituted alkyl is —CH 2 CH 2 CH 2 —OH);

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(6) R 8 is as defined for formula I;

(7) R 1 is as defined for formula I;

(8) V is a bond; and

(9) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) aryl (e.g., phenyl), (b) aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said aryl is substituted with 1 to 3 halos, (ii) in another example said aryl is substituted with 1 to 3 F, (iii) in another example said aryl is substituted with 3 F, (iv) in another example said aryl is substituted with 2 F, and (v) in another example said aryl is substituted with 1 F), (c) heteroaryl (e.g., thienyl), (d) heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said heteroaryl is substituted with 1 to 3 halos, (ii) in another example said heteroaryl is substituted with 1 to 3 F, and (iii) in another example said heteroaryl is substituted with 1 F), (d) cycloalkyl (e.g., cyclopropyl), (e) cycloalkyl (e.g., cyclopropyl) substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cycloalkyl is substituted with 1 to 3 halos, and (ii) in another example said cycloalkyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl), (g) alkyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said alkyl is substituted with one —OR 15 group, (ii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is H, (iii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl-, (iv) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl- and R 18 is —OH and r is 1, and (v) in another example said alkyl is substituted with one —OR 15 wherein R 15 is HO—CH 2 —, or HO—(CH 2 ) 2 —); and

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(6) R 8 is as defined for formula I;

(7) R 1 is as defined for formula I;

(8) V is a bond; and

(9) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(6) R 8 is as defined for formula I;

(7) R 1 is as defined for formula I;

(8) V is a bond; and

(9) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z17 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of H, alkyl (e.g., methyl, ethyl and propyl, and in one example propyl), and alkyl (e.g., methyl, ethyl and propyl) substituted with 1 —OH group (and in one example the substituted alkyl is —CH 2 CH 2 CH 2 —OH);

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(6) R 8 is as defined for formula I;

(7) R 1 is as defined for formula I;

(8) V is a bond; and

(9) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 2 , R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein the R 9 —R 10 — group is 50b, and V, R 2 , R 3 , R 4 , R 6 and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) aryl (e.g., phenyl), (b) aryl (e.g., phenyl) substituted with 1 to 3 independently selected

R 21 groups (and (i) in one example said aryl is substituted with 1 to 3 halos, (ii) in another example said aryl is substituted with 1 to 3 F, (iii) in another example said aryl is substituted with 3 F, (iv) in another example said aryl is substituted with 2 F, and (v) in another example said aryl is substituted with 1 F),

(c) heteroaryl (e.g., thienyl), (d) heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said heteroaryl is substituted with 1 to 3 halos, (ii) in another example said heteroaryl is substituted with 1 to 3 F, and (iii) in another example said heteroaryl is substituted with 1 F), (d) cycloalkyl (e.g., cyclopropyl), (e) cycloalkyl (e.g., cyclopropyl) substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cycloalkyl is substituted with 1 to 3 halos, and (ii) in another example said cycloalkyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl), (g) alkyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said alkyl is substituted with one —OR 15 group, (ii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is H, (iii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl-, (iv) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl- and R 18 is —OH and r is 1, and (v) in another example said alkyl is substituted with one —OR 15 wherein R 15 is HO—CH 2 —, or HO—(CH 2 ) 2 —); and

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ; and

(6) V is a bond; and

(7) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ; and

(6) V is a bond; and

(7) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of H, alkyl (e.g., methyl, ethyl and propyl, and in one example propyl), and alkyl (e.g., methyl, ethyl and propyl) substituted with 1 —OH group (and in one example the substituted alkyl is —CH 2 CH 2 CH 2 —OH);

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ; and

(6) V is a bond; and

(7) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) aryl (e.g., phenyl), (b) aryl (e.g., phenyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said aryl is substituted with 1 to 3 halos, (ii) in another example said aryl is substituted with 1 to 3 F, (iii) in another example said aryl is substituted with 3 F, (iv) in another example said aryl is substituted with 2 F, and (v) in another example said aryl is substituted with 1 F), (c) heteroaryl (e.g., thienyl), (d) heteroaryl (e.g., thienyl) substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said heteroaryl is substituted with 1 to 3 halos, (ii) in another example said heteroaryl is substituted with 1 to 3 F, and (iii) in another example said heteroaryl is substituted with 1 F), (d) cycloalkyl (e.g., cyclopropyl), (e) cycloalkyl (e.g., cyclopropyl) substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cycloalkyl is substituted with 1 to 3 halos, and (ii) in another example said cycloalkyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl), (g) alkyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said alkyl is substituted with one —OR 15 group, (ii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is H, (iii) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl-, (iv) in another example said alkyl is substituted with one —OR 15 group wherein R 15 is (R 18 ) r -alkyl- and R 18 is —OH and r is 1, and (v) in another example said alkyl is substituted with one —OR 15 wherein R 15 is HO—CH 2 —, or HO—(CH 2 ) 2 —); and

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ; and

(6) V is a bond; and

(7) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups;

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ; and

(6) V is a bond; and

(7) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z18 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of H, alkyl (e.g., methyl, ethyl and propyl, and in one example propyl), and alkyl (e.g., methyl, ethyl and propyl) substituted with 1 —OH group (and in one example the substituted alkyl is —CH 2 CH 2 CH 2 —OH);

(3) one of R 3 or R 4 is H, and the remaining R 3 or R 4 is selected from the group comprising:

(a) phenyl, (b) phenyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said phenyl is substituted with 1 to 3 halos, (ii) in another example said phenyl is substituted with 1 to 3 F, (iii) in another example said phenyl is substituted with 3 F, (iv) in another example said phenyl is substituted with 2 F, and (v) in another example said phenyl is substituted with 1 F), (c) thienyl, (d) thienyl substituted with 1 to 3 independently selected R 21 groups (and (i) in one example said thienyl is substituted with 1 to 3 halos, (ii) in another example said thienyl is substituted with 1 to 3 F, and (iii) in another example said thienyl is substituted with 1 F), (d) cyclopropyl, (e) cyclopropyl substituted with 1 to 3 independently R 21 substituents (and (i) in one example said cyclopropyl is substituted with 1 to 3 halos, and (ii) in another example said cyclopropyl is substituted with 1 to 3 F), (f) alkyl (e.g., methyl or ethyl, and (i) in one example methyl, and (ii) in another example ethyl), (g) -alkyl-OH (and in one example —(CH 2 ) 3 OH), (h) -alkyl-O-alkyl-OH (and in one example —CH 2 —O—CH 2 CH 2 —OH),

(4) R 6 is H;

(5) R 7 is selected from the group consisting of; H, and phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ; and

(6) V is a bond; and

(7) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z19 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z19 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z19 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z19 wherein the R 9 —R 10 — group is 50b, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z19 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) R 8 is as defined for formula I;

(6) R 1 is as defined for formula I;

(7) V is a bond; and

(8) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z19 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) R 8 is as defined for formula I;

(6) R 1 is as defined for formula I;

(7) V is a bond; and

(8) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z20 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z20 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z20 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z20 wherein the R 9 —R 10 — group is 50b, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z20 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) V is a bond; and

(6) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z20 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) V is a bond; and

(6) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z21 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z21 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z21 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z21 wherein the R 9 —R 10 — group is 50b, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z21 wherein:

(1) the R 9 -R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) R 8 is as defined for formula I;

(6) R 1 is as defined for formula I;

(7) V is a bond; and

(8) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z21 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) R 8 is as defined for formula I;

(6) R 1 is as defined for formula I;

(7) V is a bond; and

(8) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z22 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z22 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z22 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z22 wherein the R 9 —R 10 — group is 50b, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z22 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) V is a bond; and

(6) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z22 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) V is a bond; and

(6) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z23 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z23 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z23 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z23 wherein the R 9 —R 10 — group is 50b, and V, R 1 , R 2 , R 3 or R 4 , R 7 and R 8 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z23 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) R 8 is as defined for formula I;

(6) R 1 is as defined for formula I;

(7) V is a bond; and

(8) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z23 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) R 8 is as defined for formula I;

(6) R 1 is as defined for formula I;

(7) V is a bond; and

(8) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z24 wherein R 9 is selected from the group consisting of 1 g to 52 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z24 wherein R 9 is selected from the group consisting of 1 g to 13 g, R 10 is selected from the group consisting of 1A to 55A, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z24 wherein the R 9 —R 10 — group is selected from the group consisting of 1b to 53b, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z24 wherein the R 9 —R 10 — group is 50b, and V, R 2 , R 3 or R 4 , and R 7 are as defined for formula I.

Another embodiment of this invention is directed to a compound of formula I having the formula Z24 wherein:

(1) the R 9 —R 10 — group is selected from the group consisting of 1b to 53b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) V is a bond; and

(6) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

Another embodiment of this invention is directed to a compound of formula I having the formula Z24 wherein:

(1) the R 9 —R 10 — group is 50b;

(2) R 2 is selected from the group consisting of (a) H, (b) alkyl, and (c) alkyl substituted with 1 to 5 R 21 groups, and in one example R 2 is alkyl (e.g., methyl), and in another example R 2 is H;

(3) R 3 (or R 4 ) is H,

(4) R 7 is phenyl substituted with 1 to 3 substituents selected from the group consisting of: halo (e.g., F), —SF 5 and —OSF 5 ;

(5) V is a bond; and

(6) (i) in one example R 7 is phenyl substituted with 1 to 3 halos, (ii) in another example R 7 is phenyl substituted with 1 to 3 F, (iii) in another example R 7 is phenyl substituted with 3 F, (iv) in another example R 7 is phenyl substituted with 2 F, (v) in another example R 7 is phenyl substituted with one F, (vi) in another example R 7 is phenyl substituted with one —SF 5 group, and (vii) in another example R 7 is phenyl substituted with one —OSF 5 group.

In the embodiments below Groups A, B, C and D are as defined as follows:

(1) Group A: compounds Z1 to Z24; (2) Group B: compounds 1 to 117, the final compound of Method T and the final compound of Method U; (3) Group C: compounds 1 to 68; and (4) Group D: compounds 69 to 117.

Another embodiment of this invention is directed to compounds of formula I.

Another embodiment of this invention is directed to a compound of formula I selected from the group consisting of Group A.

Another embodiment of this invention is directed to a pharmaceutically acceptable salt of a compound of formula I. And in one example the salt is a salt of a compound selected from the group consisting of Group A. And in another example the salt is a salt of a compound selected from the group consisting of Group B. And in another example the salt is a salt of a compound selected from the group consisting of Group C. And in another example the salt is a salt of a compound selected from the group consisting of Group D.

Another embodiment of this invention is directed to a pharmaceutically acceptable ester of a compound of formula I. And in one example the ester is an ester of a compound selected from the group consisting of Group A. And in another example the ester is an ester of a compound selected from the group consisting of Group B. And in another example the ester is an ester of a compound selected from the group consisting of Group C. And in another example the ester is an ester of a compound selected from the group consisting of Group D.

Another embodiment of this invention is directed to a solvate of a compound of formula I. And in one example the solvate is a solvate of a compound selected from the group consisting of Group A. And in another example the solvate is a solvate of a compound selected from the group consisting of Group B. And in another example the solvate is a solvate of a compound selected from the group consisting of Group C. And in another example the solvate is a solvate of a compound selected from the group consisting of Group D.

Another embodiment of this invention is directed to a compound of formula I in pure and isolated form. And in one example the compound of formula I is selected from the group consisting of Group C. And in one example the compound of formula I is selected from the group consisting of Group D.

Another embodiment of this invention is directed to a compound of formula I in pure form. And in one example the compound of formula I is selected from the group consisting of Group C. And in one example the compound of formula I is selected from the group consisting of Group D.

Another embodiment of this invention is directed to a compound of formula I in isolated form. And in one example the compound of formula I is selected from the group consisting of Group C. And in one example the compound of formula I is selected from the group consisting of Group D.

Another embodiment of this invention is directed to a compound of formula I selected from the group consisting of Group B.

Another embodiment of this invention is directed to a compound of formula I selected from the group consisting of Group C.

Another embodiment of this invention is directed to a compound of formula I selected from the group consisting of Group D

Another embodiment of this invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable salt of one or more (e.g., one) compounds of formula I and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable ester of one or more (e.g., one) compounds of formula I and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of a solvate of one or more (e.g., one) compounds of formula I and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and an effective amount of one or more (e.g., one) other pharmaceutically active ingredients (e.g., drugs), and a pharmaceutically acceptable carrier. Examples of the other pharmaceutically active ingredients include, but are not limited to drugs selected form the group consisting of: (a) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase.

Another embodiment of this invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and a therapeutically effective amount of one or more compounds selected from the group consisting of cholinesterase inhibitors, Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more BACE inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more cholinesterase inhibitors (e.g., acetyl- and/or butyrylchlolinesterase inhibitors), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more muscarinic antagonists (e.g., m 1 or m 2 antagonists), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of Exelon (rivastigmine), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of Cognex (tacrine), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of a Tau kinase inhibitor, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more Tau kinase inhibitor (e.g., GSK3 beta inhibitor, cdk5 inhibitor, ERK inhibitor), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one anti-Abeta vaccine (active immunization), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more APP ligands, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more agents that upregulate insulin degrading enzyme and/or neprilysin, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more cholesterol lowering agents (for example, statins such as Atorvastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, and cholesterol absorption inhibitor such as Ezetimibe), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more fibrates (for example, clofibrate, Clofibride, Etofibrate, Aluminium Clofibrate), and a pharmaceutically acceptable carrier

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more LXR agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more LRP mimics, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more 5-HT6 receptor antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more nicotinic receptor agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more H3 receptor antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more histone deacetylase inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more hsp90 inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more m1 muscarinic receptor agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to combinations, i.e., a pharmaceutical composition, comprising a pharmaceutically acceptable carrier, an effective (i.e., therapeutically effective) amount of one or more compounds of formula I, in combination with an effective (i.e., therapeutically effective) amount of one or more compounds selected from the group consisting of cholinesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept® brand of donepezil hydrochloride), Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more 5-HT6 receptor antagonists mGluR1 or mGluR5 positive allosteric modulators or agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more one mGluR2/3 antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more anti-inflammatory agents that can reduce neuroinflammation, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more Prostaglandin EP2 receptor antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more PAI-1 inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula I, and effective amount of one or more agents that can induce Abeta efflux such as gelsolin, and a pharmaceutically acceptable carrier.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula I is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula I is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula I is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula I is selected from the group consisting of Group D.

The compounds of formula I can be useful as gamma secretase modulators and can be useful in the treatment and prevention of diseases such as, for example, central nervous system disorders (such as Alzheimers disease and Downs Syndrome), mild cognitive impairment, glaucoma, cerebral amyloid angiopathy, stroke, dementia, microgliosis, brain inflammation, and olfactory function loss.

Another embodiment of this invention is directed to a method of treating a central nervous system disorder comprising administering a therapeutically effective amount of at least one compound of Formula I to a patient in need of such treatment.

Another embodiment of this invention is directed to a method of treating a central nervous system disorder comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a method of treating a central nervous system disorder comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and a therapeutically effective amount of one or more compounds selected from the group consisting of cholinesterase inhibitors, Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Another embodiment of this invention is directed to a method for modulating (including inhibiting, antagonizing and the like) gamma-secretase comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of such treatment.

Another embodiment of this invention is directed to a method for modulating (including inhibiting, antagonizing and the like) gamma-secretase, comprising administering an effective amount of a compound of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating one or more neurodegenerative diseases, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating one or more neurodegenerative diseases, comprising administering an effective amount of a compound of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), comprising administering an effective amount of a compound of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of a compound of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating mild cognitive impairment, glaucoma, cerebral amyloid angiopathy, stroke, dementia, microgliosis, brain inflammation, or olfactory function loss, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating mild cognitive impairment, glaucoma, cerebral amyloid angiopathy, stroke, dementia, microgliosis, brain inflammation, or olfactory function loss, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating mild cognitive impairment, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating glaucoma, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating cerebral amyloid angiopathy, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating stroke, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating dementia, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating microgliosis, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating brain inflammation, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating olfactory function loss, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective amount of one or more (e.g., one) compounds of formula I to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective amount of a compound of formula I to a patient in need of treatment.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula I is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula I is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula I is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula I is selected from the group consisting of Group D.

This invention also provides combination therapies for (1) modulating gamma-secretase, or (2) treating one or more neurodegenerative diseases, or (3) inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (4) treating Alzheimer's disease. The combination therapies are directed to methods comprising the administration of an effective amount of one or more (e.g. one) compounds of formula I and the administration of an effective amount of one or more (e.g., one) other pharmaceutical active ingredients (e.g., drugs). The compounds of formula I and the other drugs can be administered separately (i.e., each is in its own separate dosage form), or the compounds of formula I can be combined with the other drugs in the same dosage form.

Thus, other embodiments of this invention are directed to any one of the methods of treatment, or methods of inhibiting, described herein, wherein an effective amount of the compound of formula I is used in combination with an effective amount of one or more other pharmaceutically active ingredients (e.g., drugs). The other pharmaceutically active ingredients (i.e., drugs) are selected from the group consisting of: BACE inhibitors (beta secretase inhibitors), muscarinic antagonists (e.g., m1 agonists or m 2 antagonists), cholinesterase inhibitors (e.g., acetyl- and/or butyrylchlolinesterase inhibitors); gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABA A inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors; Exelon (rivastigmine); Cognex (tacrine); Tau kinase inhibitors (e.g., GSK3beta inhibitors, cdk5 inhibitors, or ERK inhibitors); anti-Abeta vaccine; APP ligands; agents that upregulate insulin cholesterol lowering agents (for example, statins such as Atorvastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin); cholesterol absorption inhibitors (such as Ezetimibe); fibrates (such as, for example, for example, clofibrate, Clofibride, Etofibrate, and Aluminium Clofibrate); LXR agonists; LRP mimics; nicotinic receptor agonists; H3 receptor antagonists; histone deacetylase inhibitors; hsp90 inhibitors; m1 muscarinic receptor agonists; 5-HT6 receptor antagonists; mGluR1; mGluR5; positive allosteric modulators or agonists; mGluR2/3 antagonists; anti-inflammatory agents that can reduce neuroinflammation; Prostaglandin EP2 receptor antagonists; PAI-1 inhibitors; and agents that can induce Abeta efflux such as gelsolin.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more (e.g., one) compounds of formula I, in combination with an effective (i.e., therapeutically effective) amount of one or more cholinesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept® brand of donepezil hydrochloride), to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of a compound of formula I, in combination with an effective amount of one or more (e.g., one) cholinesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept® brand of donepezil hydrochloride), to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more (e.g., one) compounds of formula I, in combination with an effective amount of one or more compounds selected from the group consisting of Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more (e.g., one) compounds of formula I, in combination with an effective amount of one or more BACE inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of Exelon (rivastigmine).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of Cognex (tacrine).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of a Tau kinase inhibitor.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more Tau kinase inhibitor (e.g., GSK3beta inhibitor, cdk5 inhibitor, ERK inhibitor).

This invention also provides a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one anti-Abeta vaccination (active immunization).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more APP ligands.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more agents that upregulate insulin degrading enzyme and/or neprilysin.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more cholesterol lowering agents (for example, statins such as Atorvastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, and cholesterol absorption inhibitor such as Ezetimibe).

This invention also provides a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more fibrates (for example, clofibrate, Clofibride, Etofibrate, Aluminium Clofibrate).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more LXR agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more LRP mimics.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more 5-HT6 receptor antagonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more nicotinic receptor agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more H3 receptor antagonists.

This invention also provides a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more histone deacetylase inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more hsp90 inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more m1 muscarinic receptor agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more 5-HT6 receptor antagonists mGluR1 or mGluR5 positive allosteric modulators or agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more mGiuR2/3 antagonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more anti-inflammatory agents that can reduce neuroinflammation.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more Prostaglandin EP2 receptor antagonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more PAM-1 inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more agents that can induce Abeta efflux such as gelsolin.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective amount of one or more (e.g., one) compounds of formula I, in combination with an effective amount of one or more cholinesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept® brand of donepezil hydrochloride), to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective amount of a compound of formula I, in combination with an effective amount of one or more (e.g., one) cholinesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept® brand of donepezil hydrochloride), to a patient in need of treatment.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula I are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula I is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula I are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula I is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula I are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula I is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula I are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula I is selected from the group consisting of Group D.

This invention also provides a kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of formula I in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described above), the combined quantities of the compound of formula I and the other pharmaceutically active ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma-secretase, or (e) mild cognitive impairment, or (f) glaucoma, or (g) cerebral amyloid angiopathy, or (h) stroke, or (i) dementia, or (j) microgliosis, or (k) brain inflammation, or (l) olfactory function loss.

This invention also provides a kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of formula I in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described above), the combined quantities of the compound of formula I and the other pharmaceutically active ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma-secretase.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula I is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula I is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula I is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula I is selected from the group consisting of Group D.

As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

“ADDP” means 1,1′-(azodicarbonyl)dipiperidine.

“AIBN” means 2,2′-azobis(2-methylpropionitrile).

“CAN” means ammonium cerium (IV) nitrate.

“DCC” means N,N′-dicyclohexylcarbodiimide.

“DCM” means dichloromethane.

“(DHQ) 2 PHAL” means

“DMF” means dimethylformamide.

“EDCI” means N-ethyl-N′-dimethylaminopropyl carbodiimide.

“HOBT” means 1-hydroxylbenzotriazole.

“LDA” means lithium diisopropylamide.

“TBAF” means tetra-N-butylammonium fluoride.

“TBSO” means tert-butyldimethylsilyloxy.

“TEA” means triethylamine.

“TEA” means trifluoroacetic acid.

“TfO” means trifluoromethylsulfonyloxy.

“At least one” means one or more than one, for example, 1, 2 or 3, or inanother example, 1 or 2, or in another example 1.

“One or more” with reference to the use of the compounds of this invention means that one or more than one compound is used, for example, 1, 2 or 3, or in another example, 1 or 2, or in another example 1.

“Patient” includes both human and animals.

“Mammal” means humans and other mammalian animals.

It is noted that the carbons of formula I and other formulas herein may be replaced with 1 to 3 silicon atoms so long as all valency requirements are satisfied.

“Alkyl” means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. “Alkyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, oxime (e.g., ═N—OH), —NH(alkyl), —NH(cycloalkyl), —N(alkyl) 2 , —O—C(O)-alkyl, —O—C(O)-aryl, —O—C(O)-cycloalkyl, carboxy and —C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.

“Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. “Alkenyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, alkoxy and —S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

“Alkylene” means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.

“Alkynyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.

“Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. “Alkynyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.

“Aryl” means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.

“Heteroaryl” means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The “heteroaryl” can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. “Heteroaryl” may also include a heteroaryl as defined above fused to an aryl as defined above. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. The term “heteroaryl” also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.

“Aralkyl” or “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.

“Alkylaryl” means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.

“Cycloalkyl” means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like.

“Cycloalkylalkyl” means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexylmethyl, adamantylmethyl and the like.

“Cycloalkenyl” means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbornylenyl.

“Cycloalkenylalkyl” means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.

“Halogen” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine. “Halo” refers to fluoro, chloro, bromo or iodo.

“Ring system substituent” means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, —O—C(O)-alkyl, —O—C(O)-aryl, —O—C(O)-cycloalkyl, —C(═N—CN)—NH 2 , —C(═NH)—NH 2 , —C(═NH)—NH(alkyl), oxime (e.g., ═N—OH), Y 1 Y 2 N—, Y 1 Y 2 N-alkyl-, Y 1 Y 2 NC(O)—, Y 1 Y 2 NSO 2 — and —SO 2 NY 1 Y 2 , wherein Y 1 and Y 2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. “Ring system substituent” may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, —C(CH 3 ) 2 — and the like which form moieties such as, for example:

“Heteroarylalkyl” means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.

“Heterocyclyl” means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any —NH in a heterocyclyl ring may exist protected such as, for example, as an —N(Boc), —N(CBz), —N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like. “Heterocyclyl” may also mean a heterocyclyl ring wherein a single moiety (e.g ═O) simultaneously replaces two available hydrogens on the same carbon atom on a ring system. An example of such moiety is pyrrolidone:

“Heterocyclylalkyl” means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.

“Heterocyclenyl” means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein “ring system substituent” is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4- tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like. “Heterocyclenyl” may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system. Example of such moiety is pyrrolidinone:

“Heterocyclenylalkyl” means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.

It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:

there is no —OH attached directly to carbons marked 2 and 5.

It should also be noted that tautomeric forms such as, for example, the moieties:

are considered equivalent in certain embodiments of this invention.

“Alkynylalkyl” means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a tower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.

“Heteroaralkyl” means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.

“Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

“Acyl” means an H—C(O)—, alkyl-C(O)— or cycloalkyl-C(O)—, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.

“Aroyl” means an aryl-C(O)— group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.

“Alkoxy” means an alkyl-O— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.

“Aryloxy” means an aryl-O— group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.

“Aralkyloxy” means an aralkyl-O— group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.

“Alkylthio” means an alkyl-S— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.

“Arylthio” means an aryl-S— group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.

“Aralkylthio” means an aralkyl-S— group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.

“Alkoxycarbonyl” means an alkyl-O—CO— group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Aryloxycarbonyl” means an aryl-O—C(O)— group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Aralkoxycarbonyl” means an aralkyl-O—C(O)— group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Alkylsulfonyl” means an alkyl-S(O 2 )— group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.

“Arylsulfonyl” means an aryl-S(O 2 )— group. The bond to the parent moiety is through the sulfonyl.

The term “substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties.

The term “purified”, “in purified form” or “in isolated and purified form” for a compound refers to the physical state of said compound after being isolated from a synthetic process (e.g. from a reaction mixture), or natural source or combination thereof. Thus, the term “purified”, “in purified form” or “in isolated and purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization and the like), in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.

It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

When a functional group in a compound is termed “protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.

When any variable (e.g., aryl, heterocycle, R 2 , etc.) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro - drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design , (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term “prodrug” means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

For example, if a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C 1 -C 8 )alkyl, (C 2 -C 12 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N—(C 1 -C 2 )alkylamino(C 2 -C 3 )alkyl (such as β-dimethylaminoethyl), carbamoyl-(C 1 -C 2 )alkyl, N,N-di (C 1 -C 2 )alkylcarbamoyl-(C 1 -C 2 )alkyl and piperidino-, pyrrolidino- or morpholino(C 2 -C 3 )alkyl, and the like.

Similarly, if a compound of Formula (I) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C 1 -C 6 )alkanoyloxymethyl, 1-((C 1 -C 6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1 -C 6 )alkanoyloxy)ethyl, (C 1 -C 6 )alkoxycarbonyloxymethyl, N—(C 1 -C 6 )alkoxycarbonylaminomethyl, succinoyl, (C 1 -C 6 )alkanoyl, α-amino(C 1 -C 4 )alkanyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH) 2 , —P(O)(O(C 1 -C 6 )alkyl) 2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.

If a compound of Formula (I) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR′-carbonyl where R and R′ are each independently (C 1 -C 10 )alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl, —C(OH)C(O)OY 1 wherein Y 1 is H, (C 1 -C 6 )alkyl or benzyl, —C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C 1 -C 6 )alkyl, carboxy (C 1 -C 6 )alkyl, amino(C 1 -C 4 )alkyl or mono-N— or di-N,N—(C 1 -C 6 )alkylaminoalkyl, —C(Y 4 )Y 5 wherein Y 4 is H or methyl and Y 5 is mono-N— or di-N,N—(C 1 -C 6 )alkylamino morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.

One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H 2 O.

One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).

“Effective amount” or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.

The compounds of Formula I can form salts which are also within the scope of this invention. Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula I contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula I may be formed, for example, by reacting a compound of Formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G . (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use . (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.

All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C 1-4 alkyl, or C 1-4 alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C 1-20 alcohol or reactive derivative thereof, or by a 2,3-di (C 6-24 )acyl glycerol.

Compounds of Formula I, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide, enol, keto or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.

The compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.

Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers, Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.

It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.

All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.

The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.

Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, 36 Cl and 123 I, respectively.

Certain isotopically-labelled compounds of Formula (I) (e.g., those labeled with 3 H and 14 C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Certain isotopically-labelled compounds of Formula (I) can be useful for medical imaging purposes. E.g., those labeled with positron-emitting isotopes like 11 C or 18 F can be useful for application in Positron Emission Tomography (PET) and those labeled with gamma ray emitting isotopes like 123 I can be useful for application in Single photon emission computed tomography (SPECT). Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Additionally, isotopic substitution at a site where epimerization occurs may slow or reduce the epimerization process and thereby retain the more active or efficacious form of the compound for a longer period of time. Isotopically labeled compounds of Formula (I), in particular those containing isotopes with longer half lives (T½>1 day), can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.

Polymorphic forms of the compounds of Formula I, and of the salts, solvates, esters and prodrugs of the compounds of Formula I, are intended to be included in the present invention.

The compounds according to the invention can have pharmacological properties; in particular, the compounds of Formula I can be modulators of gamma secretase (including inhibitors, antagonists and the like).

More specifically, the compounds of Formula I can be useful in the treatment of a variety of disorders of the central nervous system including, for example, including, but not limited to, Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrop